489 results on '"Kiemeney, L.A.L.M."'
Search Results
2. Disease-Free Survival of Patients With Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder-Preserving Therapy: A Nationwide Study.
- Author
-
Brück, K., Meijer, R.P., Boormans, J.L., Kiemeney, L.A.L.M., Witjes, J.A., Hoogstraten, L.M.C. van, Heijden, M.S. van der, Donders, A.R.T., Franckena, M., Uyl-de Groot, C.A., Leliveld, A.M., Aben, K.K.H., Hulshof, M.C.C., Brück, K., Meijer, R.P., Boormans, J.L., Kiemeney, L.A.L.M., Witjes, J.A., Hoogstraten, L.M.C. van, Heijden, M.S. van der, Donders, A.R.T., Franckena, M., Uyl-de Groot, C.A., Leliveld, A.M., Aben, K.K.H., and Hulshof, M.C.C.
- Abstract
Item does not contain fulltext, PURPOSE: Although level I evidence is lacking that radical cystectomy (RC) is superior to bladder-preserving therapy (BPT), RC is still advocated as the recommended treatment in patients with nonmetastatic muscle-invasive bladder cancer (MIBC). This study sought to compare the survival of patients with MIBC treated with BPT versus those treated with RC. METHODS AND MATERIALS: All patients with nonmetastatic MIBC diagnoses were identified via the population-based Netherlands Cancer Registry. Only patients treated with BPT or RC were included. The primary endpoint was 2-year disease-free survival (DFS), defined as time from start of treatment until locoregional recurrence, distant metastasis, or death. The secondary endpoint was overall survival (OS). Inverse propensity treatment weighting (IPTW) was used based on propensity scores to adjust for baseline differences between treatment groups. Survival was analyzed with Kaplan-Meier and Cox proportional hazards models. RESULTS: A total of 1432 patients were included, of whom 1101 underwent RC and 331, BPT. Median follow-up was 39 months (range, 27-51 months). The IPTW-adjusted 2-year DFS was 61.5% (95% CI, 53.5%-69.6%) with BPT and 55.3% (95% CI, 51.6%-59.1%) with RC, with an adjusted hazard ratio of 0.84 (95% CI, 0.69-1.05). The adjusted 2-year OS for patients treated with BPT versus RC was 74.0% (95% CI, 67.0%-80.9%) versus 66.0% (95% CI, 62.7%-68.8%), respectively, with an adjusted hazard ratio of 0.80 (95% CI, 0.64-0.98). CONCLUSIONS: There was no statistically significant difference between the 2-year DFS of patients treated with BPT and RC. We propose that both RC and BPT should be offered as a curative treatment option to eligible patients with nonmetastatic MIBC.
- Published
- 2024
3. Multi-trait analysis characterizes the genetics of thyroid function and identifies causal associations with clinical implications
- Author
-
Sterenborg, R.B.T.M., Steinbrenner, I., Li, Yong, Bujnis, M.N., Naito, T., Marouli, E., Galesloot, T.E., Babajide, O., Andreasen, L., Astrup, A., Åsvold, B.O., Bandinelli, S., Beekman, M., Beilby, J.P., Bork-Jensen, J., Boutin, T., Brody, J.A., Brown, S.J., Brumpton, B., Campbell, P.J., Cappola, A.R., Ceresini, G., Chaker, L., Chasman, D.I., Concas, M.P., Coutinho de Almeida, Rodrigo, Cross, S.M., Cucca, F., Deary, I.J., Kjaergaard, A.D., Echouffo Tcheugui, J.B., Ellervik, C., Eriksson, J.G., Ferrucci, L., Freudenberg, J., Fuchsberger, C., Gieger, C., Giulianini, F., Gögele, M., Graham, S.E., Grarup, N., Gunjača, I., Hansen, T., Harding, B.N., Harris, S.E., Haunsø, S., Hayward, C., Hui, J., Ittermann, T., Jukema, J.W., Kajantie, E., Kanters, J.K., Kårhus, L.L., Kiemeney, L.A.L.M., Kühnel, B., Lahti, J., Langenberg, C., Lapauw, B., Leese, G., Li, Shuo, Liewald, D.C.M., Linneberg, A., Lominchar, J.V.T., Luan, Jian'an, Martin, N.G., Matana, A., Meima, M.E., Meitinger, T., Meulenbelt, I., Mitchell, B.D., Møllehave, L.T., Mora, S., Naitza, S., Nauck, M., Netea-Maier, R.T., Noordam, R., Nursyifa, C., Okada, Y., Onano, S., Papadopoulou, A., Palmer, C.N.A., Pattaro, C., Pedersen, O., Peters, A., Pietzner, M., Polašek, O., Pramstaller, P.P., Psaty, B.M., Punda, A., Ray, D., Redmond, P., Richards, J.B., Ridker, P.M., Russ, T.C., Ryan, K.A., Olesen, M.S., Schultheiss, U.T., Selvin, E., Siddiqui, M.K., Teumer, A., Medici, M., Sterenborg, R.B.T.M., Steinbrenner, I., Li, Yong, Bujnis, M.N., Naito, T., Marouli, E., Galesloot, T.E., Babajide, O., Andreasen, L., Astrup, A., Åsvold, B.O., Bandinelli, S., Beekman, M., Beilby, J.P., Bork-Jensen, J., Boutin, T., Brody, J.A., Brown, S.J., Brumpton, B., Campbell, P.J., Cappola, A.R., Ceresini, G., Chaker, L., Chasman, D.I., Concas, M.P., Coutinho de Almeida, Rodrigo, Cross, S.M., Cucca, F., Deary, I.J., Kjaergaard, A.D., Echouffo Tcheugui, J.B., Ellervik, C., Eriksson, J.G., Ferrucci, L., Freudenberg, J., Fuchsberger, C., Gieger, C., Giulianini, F., Gögele, M., Graham, S.E., Grarup, N., Gunjača, I., Hansen, T., Harding, B.N., Harris, S.E., Haunsø, S., Hayward, C., Hui, J., Ittermann, T., Jukema, J.W., Kajantie, E., Kanters, J.K., Kårhus, L.L., Kiemeney, L.A.L.M., Kühnel, B., Lahti, J., Langenberg, C., Lapauw, B., Leese, G., Li, Shuo, Liewald, D.C.M., Linneberg, A., Lominchar, J.V.T., Luan, Jian'an, Martin, N.G., Matana, A., Meima, M.E., Meitinger, T., Meulenbelt, I., Mitchell, B.D., Møllehave, L.T., Mora, S., Naitza, S., Nauck, M., Netea-Maier, R.T., Noordam, R., Nursyifa, C., Okada, Y., Onano, S., Papadopoulou, A., Palmer, C.N.A., Pattaro, C., Pedersen, O., Peters, A., Pietzner, M., Polašek, O., Pramstaller, P.P., Psaty, B.M., Punda, A., Ray, D., Redmond, P., Richards, J.B., Ridker, P.M., Russ, T.C., Ryan, K.A., Olesen, M.S., Schultheiss, U.T., Selvin, E., Siddiqui, M.K., Teumer, A., and Medici, M.
- Abstract
Contains fulltext : 304858.pdf (Publisher’s version ) (Open Access), To date only a fraction of the genetic footprint of thyroid function has been clarified. We report a genome-wide association study meta-analysis of thyroid function in up to 271,040 individuals of European ancestry, including reference range thyrotropin (TSH), free thyroxine (FT4), free and total triiodothyronine (T3), proxies for metabolism (T3/FT4 ratio) as well as dichotomized high and low TSH levels. We revealed 259 independent significant associations for TSH (61% novel), 85 for FT4 (67% novel), and 62 novel signals for the T3 related traits. The loci explained 14.1%, 6.0%, 9.5% and 1.1% of the total variation in TSH, FT4, total T3 and free T3 concentrations, respectively. Genetic correlations indicate that TSH associated loci reflect the thyroid function determined by free T3, whereas the FT4 associations represent the thyroid hormone metabolism. Polygenic risk score and Mendelian randomization analyses showed the effects of genetically determined variation in thyroid function on various clinical outcomes, including cardiovascular risk factors and diseases, autoimmune diseases, and cancer. In conclusion, our results improve the understanding of thyroid hormone physiology and highlight the pleiotropic effects of thyroid function on various diseases.
- Published
- 2024
4. Minimum Volume Standards: An Incentive To Perform More Radical Cystectomies?
- Author
-
Nuijens, S.T., Hoogstraten, L.M.C. van, Meijer, R.P., Kiemeney, L.A.L.M., Aben, K.K.H., and Witjes, J.A.
- Subjects
All institutes and research themes of the Radboud University Medical Center ,Urological cancers Radboud Institute for Health Sciences [Radboudumc 15] ,Urology ,Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15] - Abstract
Contains fulltext : 292901.pdf (Publisher’s version ) (Open Access) BACKGROUND: Minimum volume standards (MVS) for hospitals and/or surgeons remain a subject of debate. Opponents of MVS emphasize the possible negative effects of centralization, such as an unwanted incentive to perform surgery. OBJECTIVE: To evaluate whether the introduction of MVS for radical cystectomy (RC) in the Netherlands resulted in more RCs outside guideline-recommended indications. DESIGN SETTING AND PARTICIPANTS: All RCs performed for bladder cancer in the Netherlands between January 1, 2006 and December 31, 2017 were identified in the Netherlands Cancer Registry. During this period, two MVS were sequentially implemented for RC. RCs in intermediate-volume hospitals (hospitals that approximated the MVS) were compared with RCs in high-volume hospitals (hospitals exceeding the MVS by ≥5 RCs/yr) in a period before and a period after implementation of each of the two MVS. OUTCOMES MEASUREMENTS AND STATISTICAL ANALYSIS: Descriptive analyses were performed to evaluate whether hospitals performed more RCs outside the recommended indication (cT2-4a N0 M0) and whether an increase in the number of RCs towards the end of the year could be observed. RESULTS AND LIMITATIONS: After MVS implementation, no clear shift towards disease stages outside the recommended indication for RC was observed in comparison to the period before the MVS. Results for high-volume and intermediate-volume hospitals were similar. In addition, no increase in RCs towards the end of the year was evident. CONCLUSIONS: We did not find evidence indicating an unwanted incentive to perform more RCs as a result of MVS in the Netherlands. Our results further strengthen the case for MVS implementation. PATIENT SUMMARY: We evaluated whether criteria for the minimum number of radical cystectomies (surgical removal of the bladder) that hospitals have to perform caused urologists to perform more of these operations than necessary in order to meet the minimum level. We found no evidence that minimum criteria led to such an unwanted incentive.
- Published
- 2023
5. Development and external validation of multivariate prediction models for erectile dysfunction in men with localized prostate cancer.
- Author
-
Hasannejadasl, H., Roumen, C., Poel, H. van der, Vanneste, B., Roermund, J. van, Aben, K.K.H., Kalendralis, P., Osong, B., Kiemeney, L.A.L.M., Oort, I.M. van, Verwey, R., Hochstenbach, L., loemen-van Gurp, E. J B, Dekker, A., Fijten, R.R.R., Hasannejadasl, H., Roumen, C., Poel, H. van der, Vanneste, B., Roermund, J. van, Aben, K.K.H., Kalendralis, P., Osong, B., Kiemeney, L.A.L.M., Oort, I.M. van, Verwey, R., Hochstenbach, L., loemen-van Gurp, E. J B, Dekker, A., and Fijten, R.R.R.
- Abstract
Item does not contain fulltext, While the 10-year survival rate for localized prostate cancer patients is very good (>98%), side effects of treatment may limit quality of life significantly. Erectile dysfunction (ED) is a common burden associated with increasing age as well as prostate cancer treatment. Although many studies have investigated the factors affecting erectile dysfunction (ED) after prostate cancer treatment, only limited studies have investigated whether ED can be predicted before the start of treatment. The advent of machine learning (ML) based prediction tools in oncology offers a promising approach to improve the accuracy of prediction and quality of care. Predicting ED may help aid shared decision-making by making the advantages and disadvantages of certain treatments clear, so that a tailored treatment for an individual patient can be chosen. This study aimed to predict ED at 1-year and 2-year post-diagnosis based on patient demographics, clinical data and patient-reported outcomes (PROMs) measured at diagnosis. We used a subset of the ProZIB dataset collected by the Netherlands Comprehensive Cancer Organization (Integraal Kankercentrum Nederland; IKNL) that contained information on 964 localized prostate cancer cases from 69 Dutch hospitals for model training and external validation. Two models were generated using a logistic regression algorithm coupled with Recursive Feature Elimination (RFE). The first predicted ED 1 year post-diagnosis and required 10 pre-treatment variables; the second predicted ED 2 years post-diagnosis with 9 pre-treatment variables. The validation AUCs were 0.84 and 0.81 for 1 year and 2 years post-diagnosis respectively. To immediately allow patients and clinicians to use these models in the clinical decision-making process, nomograms were generated. In conclusion, we successfully developed and validated two models that predicted ED in patients with localized prostate cancer. These models will allow physicians and patients alike to make informed eviden
- Published
- 2023
6. Longitudinal associations of adherence to lifestyle recommendations and health-related quality of life in patients with non-muscle invasive bladder cancer.
- Author
-
Vidra, N., Beeren, I., Zutphen, M. van, Aben, K.K.H., Kampman, E., Witjes, J.A., Heijden, A.G. van der, Kiemeney, L.A.L.M., Vrieling, A., Vidra, N., Beeren, I., Zutphen, M. van, Aben, K.K.H., Kampman, E., Witjes, J.A., Heijden, A.G. van der, Kiemeney, L.A.L.M., and Vrieling, A.
- Abstract
Item does not contain fulltext, Although the role of lifestyle in health-related quality of life (HRQoL) outcomes has been increasingly recognized for various types of cancer, evidence in patients with non-muscle invasive bladder cancer (NMIBC) is very limited. We aimed to evaluate the longitudinal association between adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) lifestyle recommendations and HRQoL in patients with NMIBC. This study included 1029 patients with NMIBC recruited between May 2014 and April 2017 from the Dutch multi-centre prospective cohort study UroLife. Lifestyle and HRQoL data were collected at 6 weeks (baseline), 3 months and 15 months after diagnosis. Information on body mass index (BMI), physical activity, diet and alcohol was used to compute the standardized WCRF/AICR adherence score (0-7). HRQoL outcomes were evaluated by the EORTC QLQ-C30. Linear mixed models were used to assess longitudinal confounder-adjusted associations between the WCRF/AICR adherence score and HRQoL outcomes. Adherence to each additional WCRF/AICR recommendation was associated with better global quality of life, physical, role and social functioning, and less fatigue. We found stronger inter-individual than intra-individual associations, suggesting that associations were mainly driven by between-subject differences. Higher adherence to the BMI, physical activity and dietary recommendations was associated with better scores for most HRQoL outcomes, while adherence to the alcohol recommendation (ie, non-consumption) was associated with worse HRQoL. Following the WCRF/AICR lifestyle recommendations may improve HRQoL in patients with NMIBC. Intervention studies are needed to establish whether the association between lifestyle and HRQoL is causal.
- Published
- 2023
7. Role of multidisciplinary team meetings in implementation of chemohormonal therapy in metastatic prostate cancer in daily practice.
- Author
-
Creemers, S.G., Santvoort, B. van, Berkmortel, F.W.P.J. van den, Kiemeney, L.A.L.M., Oort, I.M. van, Aben, K.K.H., Hamberg, P., Creemers, S.G., Santvoort, B. van, Berkmortel, F.W.P.J. van den, Kiemeney, L.A.L.M., Oort, I.M. van, Aben, K.K.H., and Hamberg, P.
- Abstract
Item does not contain fulltext, BACKGROUND: The recommended treatment for a subset of patients with metastatic prostate cancer (mPC) changed from androgen deprivation therapy (ADT) to combinations with chemotherapy such as docetaxel. Implementation of new evidence from trials is however complex and challenging. We investigated the effect of multidisciplinary team meetings (MDTs) on adopting the newest emerging combination therapy in patients with mPC and assessed the overall survival of chemohormonal therapy in a real-world setting. METHODS: All mPC patients diagnosed between October 2015 and April 2016 in the Netherlands were identified from the population-based Netherlands Cancer Registry (n = 962). Logistic regression analyses were performed to examine the role of patient- and tumor characteristics, with special emphasis on MDTs, on receiving chemohormonal therapy versus ADT monotherapy. Kaplan-Meier survival curves were used to assess overall survival (OS). RESULTS: As many patients received ADT monotherapy as chemohormonal therapy (both n = 452). Being discussed in a MDT as patient, younger age, less comorbidities, a better performance status and high-volume disease were significantly associated with receiving chemohormonal therapy compared to ADT monotherapy. After adjustment for these factors, the presence of a MDT was independently associated with the administration of chemohormonal therapy (OR 2.77, 95% CI 1.68-4.59). The 2-year OS was 82.1% (95% CI: 78.5-85.6%) for patients receiving chemohormonal therapy and 59.9% (95% CI: 55.4-64.4%) for patients receiving ADT monotherapy. CONCLUSION: Being discussed in a MDT is independently associated with the administration of chemohormonal therapy in this group of patients with mPC. This supports the hypothesis that implementation of innovative treatment options is facilitated by an organizational structure with MDTs.
- Published
- 2023
8. Sociodemographic, lifestyle and clinical characteristics of energy-related depression symptoms: A pooled analysis of 13,965 depressed cases in 8 Dutch cohorts
- Author
-
Vreijling, S.R., Haeringen, Marije van, Milaneschi, Yuri, Huider, Floris, Bot, Mariska, Bot, Najaf, Galesloot, T.E., Kiemeney, L.A.L.M., Lamers, Femke, Jansen, Rick, Vreijling, S.R., Haeringen, Marije van, Milaneschi, Yuri, Huider, Floris, Bot, Mariska, Bot, Najaf, Galesloot, T.E., Kiemeney, L.A.L.M., Lamers, Femke, and Jansen, Rick
- Abstract
Item does not contain fulltext
- Published
- 2023
9. Body composition and clinical outcomes in renal cell cancer
- Author
-
Kiemeney, L.A.L.M., Vrieling, A., Sedelaar, J.P.M., Maurits, J.S.F., Kiemeney, L.A.L.M., Vrieling, A., Sedelaar, J.P.M., and Maurits, J.S.F.
- Abstract
Radboud University, 01 februari 2023, Promotor : Kiemeney, L.A.L.M. Co-promotores : Vrieling, A., Sedelaar, J.P.M., Contains fulltext : 288647.pdf (Publisher’s version ) (Closed access)
- Published
- 2023
10. An Association Study of Germline Variants in Bladder Cancer-Related Genes with the Prognosis of Non-Muscle Invasive Bladder Cancer
- Author
-
Hof, J.P., Vermeulen, H.H., Heijden, A.G. van der, Verhaegh, G.W., Dyrskjøt, L., Catto, James W. F., Kiemeney, L.A.L.M., Galesloot, T.E., Hof, J.P., Vermeulen, H.H., Heijden, A.G. van der, Verhaegh, G.W., Dyrskjøt, L., Catto, James W. F., Kiemeney, L.A.L.M., and Galesloot, T.E.
- Abstract
Item does not contain fulltext
- Published
- 2023
11. Meta-analysis of erosive hand osteoarthritis identifies four common variants that associate with relatively large effect.
- Author
-
Styrkarsdottir, U., Stefansdottir, L., Thorleifsson, G., Stefansson, O.A., Saevarsdottir, S., Lund, S.H., Rafnar, T., Hoshijima, K., Novak, K., Oreiro, N., Rego-Perez, I., Hansen, C., Kazmers, N., Kiemeney, L.A.L.M., Blanco, F.J., Barker, T., Kloppenburg, M., Jurynec, M.J., Gudbjartsson, D.F., Jonsson, H., Thorsteinsdottir, U., Stefansson, K., Styrkarsdottir, U., Stefansdottir, L., Thorleifsson, G., Stefansson, O.A., Saevarsdottir, S., Lund, S.H., Rafnar, T., Hoshijima, K., Novak, K., Oreiro, N., Rego-Perez, I., Hansen, C., Kazmers, N., Kiemeney, L.A.L.M., Blanco, F.J., Barker, T., Kloppenburg, M., Jurynec, M.J., Gudbjartsson, D.F., Jonsson, H., Thorsteinsdottir, U., and Stefansson, K.
- Abstract
01 juni 2023, Item does not contain fulltext, OBJECTIVES: Erosive hand osteoarthritis (EHOA) is a severe subset of hand osteoarthritis (OA). It is unclear if EHOA is genetically different from other forms of OA. Sequence variants at ten loci have been associated with hand OA but none with EHOA. METHODS: We performed meta-analysis of EHOA in 1484 cases and 550 680 controls, from 5 populations. To identify causal genes, we performed eQTL and plasma pQTL analyses, and developed one zebrafish mutant. We analysed associations of variants with other traits and estimated shared genetics between EHOA and other traits. RESULTS: Four common sequence variants associated with EHOA, all with relatively high effect. Rs17013495 (SPP1/MEPE, OR=1.40, p=8.4×10(-14)) and rs11243284 (6p24.3, OR=1.35, p=4.2×10(-11)) have not been associated with OA, whereas rs11631127 (ALDH1A2, OR=1.46, p=7.1×10(-18)), and rs1800801 (MGP, OR=1.37, p=3.6×10(-13)) have previously been associated with hand OA. The association of rs1800801 (MGP) was consistent with a recessive mode of inheritance in contrast to its additive association with hand OA (OR homozygotes vs non-carriers=2.01, 95% CI 1.71 to 2.37). All four variants associated nominally with finger OA, although with substantially lower effect. We found shared genetic components between EHOA and other OA measures, grip strength, urate levels and gout, but not rheumatoid arthritis. We identified ALDH1A2, MGP and BMP6 as causal genes for EHOA, with loss-of-function Bmp6 zebrafish mutants displaying EHOA-like phenotypes. CONCLUSIONS: We report on significant genetic associations with EHOA. The results support the view of EHOA as a form of severe hand OA and partly separate it from OA in larger joints.
- Published
- 2023
12. Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population
- Author
-
Shi, J., Shiraishi, K., Choi, Jiyeon, Matsuo, K., Chen, Tsu-Yu, Dai, Juncheng, Hung, R.J., Kiemeney, L.A.L.M., Kohno, Takashi, Lan, Q., Shi, J., Shiraishi, K., Choi, Jiyeon, Matsuo, K., Chen, Tsu-Yu, Dai, Juncheng, Hung, R.J., Kiemeney, L.A.L.M., Kohno, Takashi, and Lan, Q.
- Abstract
Contains fulltext : 293210.pdf (Publisher’s version ) (Open Access)
- Published
- 2023
13. Cohort profile - the Renal cell cancer: Lifestyle, prognosis and quality of life (ReLife) study in the Netherlands.
- Author
-
Maurits, J.S.F., Sedelaar, J.P.M., Aben, K.K.H., Kampman, E., Kiemeney, L.A.L.M., Vrieling, A., Maurits, J.S.F., Sedelaar, J.P.M., Aben, K.K.H., Kampman, E., Kiemeney, L.A.L.M., and Vrieling, A.
- Abstract
Contains fulltext : 291578.pdf (Publisher’s version ) (Open Access), PURPOSE: The Renal cell cancer: Lifestyle, prognosis and quality of life (ReLife) study is set up to obtain insight into the association of patient and tumour characteristics, lifestyle habits and circulating biomarkers with body composition features in patients with localised renal cell cancer (RCC). Further, it aims to assess the association of body composition features, lifestyle habits and circulating biomarkers with clinical outcomes, including health-related quality of life. PARTICIPANTS: The ReLife study is a multicentre prospective cohort study involving 368 patients with newly diagnosed stages I-III RCC recruited from January 2018 to June 2021 from 18 hospitals in the Netherlands. At 3 months, 1 year and 2 years after treatment, participants fill out a general questionnaire and questionnaires about their lifestyle habits (eg, diet, physical activity, smoking and alcohol consumption), medical history and health-related quality of life. At all three time points, patients wear an accelerometer and have blood samples taken. CT scans for body composition analysis are being collected. Permission is asked for collection of tumour samples. Information about disease characteristics, treatment of the primary tumour and clinical outcomes is being collected from medical records by the Netherlands Cancer Registry. FINDINGS TO DATE: A total of 836 invited patients were eligible and 368 patients were willing to participate and were included (response rate 44%). The mean age of patients was 62.5±9.0 years and 70% was male. The majority had stage I (65%) disease and were treated with radical nephrectomy (57%). Data collection at 3 months and 1 years after treatment have been finalised. FUTURE PLANS: Data collection at 2 years after treatment is expected to be finalised in June 2023 and longitudinal clinical data will continue to be collected. Results of studies based on this cohort are important to develop personalised evidence-based lifestyle advice for patients with local
- Published
- 2023
14. Molecular Landscape of Pelvic Organ Prolapse Provides Insights into Disease Etiology.
- Author
-
Kluivers, K.B., Lince, S.L., Ruiz Zapata, A.M., Post, W.M., Cartwright, R., Kerkhof, M.H, Widomska, J.M., Witte, Ward De, Pecanka, J., Kiemeney, L.A.L.M., Vermeulen, S.H., Goeman, J.J., Allen-Brady, K., Oosterwijk, E., Poelmans, G.J.V., Kluivers, K.B., Lince, S.L., Ruiz Zapata, A.M., Post, W.M., Cartwright, R., Kerkhof, M.H, Widomska, J.M., Witte, Ward De, Pecanka, J., Kiemeney, L.A.L.M., Vermeulen, S.H., Goeman, J.J., Allen-Brady, K., Oosterwijk, E., and Poelmans, G.J.V.
- Abstract
Item does not contain fulltext, Pelvic organ prolapse (POP) represents a major health care burden in women, but its underlying pathophysiological mechanisms have not been elucidated. We first used a case-control design to perform an exome chip study in 526 women with POP and 960 control women to identify single nucleotide variants (SNVs) associated with the disease. We then integrated the functional interactions between the POP candidate proteins derived from the exome chip study and other POP candidate molecules into a molecular landscape. We found significant associations between POP and SNVs in 54 genes. The proteins encoded by 26 of these genes fit into the molecular landscape, together with 43 other POP candidate molecules. The POP landscape is located in and around epithelial cells and fibroblasts of the urogenital tract and harbors four interacting biological processes-epithelial-mesenchymal transition, immune response, modulation of the extracellular matrix, and fibroblast function-that are regulated by sex hormones and TGFB1. Our findings were corroborated by enrichment analyses of differential gene expression data from an independent POP cohort. Lastly, based on the landscape and using vaginal fibroblasts from women with POP, we predicted and showed that metformin alters gene expression in these fibroblasts in a beneficial direction. In conclusion, our integrated molecular landscape of POP provides insights into the biological processes underlying the disease and clues towards novel treatments.
- Published
- 2023
15. Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice.
- Author
-
Hoogstraten, L.M.C. van, Vrieling, A., Heijden, A.G. van der, Kogevinas, M., Richters, A., Kiemeney, L.A.L.M., Hoogstraten, L.M.C. van, Vrieling, A., Heijden, A.G. van der, Kogevinas, M., Richters, A., and Kiemeney, L.A.L.M.
- Abstract
Item does not contain fulltext, Bladder cancer is among the ten most common cancers globally, causes considerable morbidity and mortality and is, therefore, a substantial burden for health-care systems. The incidence of bladder cancer is affected by demographic trends, most notably population growth and ageing, as well as exposure to risk factors, especially tobacco smoking. Consequently, the incidence has not been stable throughout the world over time, nor will it be in the near future. Further primary prevention efforts are of the utmost importance to reduce the medical and financial burden of bladder cancer on populations and health-care systems. Simultaneously, less-invasive and lower-cost approaches for the diagnosis of both primary and recurrent bladder cancers are required to address challenges posed by the increasing shortage of health-care professionals and limited financial resources worldwide. In this regard, urinary biomarkers have demonstrated promising diagnostic accuracy and efficiency. Awareness of the risk factors and symptoms of bladder cancer should also be increased in society, particularly among health-care professionals and high-risk groups. Studies investigating the associations between lifestyle factors and bladder cancer outcomes are scarce and should be a research priority. In this Review, we outline global trends in bladder cancer incidence and mortality, and discuss the main risk factors influencing bladder cancer occurrence and outcomes. We then discuss the implications, challenges and opportunities of these epidemiological trends for public health and clinical practice.
- Published
- 2023
16. A comparison of machine learning models for predicting urinary incontinence in men with localized prostate cancer.
- Author
-
Hasannejadasl, H., Osong, B., Bermejo, I., Poel, H. van der, Vanneste, B., Roermund, J. van, Aben, K.K.H., Zhang, Zhen, Kiemeney, L.A.L.M., Oort, I.M. van, Verwey, R., Hochstenbach, L., Bloemen, E., Dekker, A., Fijten, R.R.R., Hasannejadasl, H., Osong, B., Bermejo, I., Poel, H. van der, Vanneste, B., Roermund, J. van, Aben, K.K.H., Zhang, Zhen, Kiemeney, L.A.L.M., Oort, I.M. van, Verwey, R., Hochstenbach, L., Bloemen, E., Dekker, A., and Fijten, R.R.R.
- Abstract
Item does not contain fulltext, INTRODUCTION: Urinary incontinence (UI) is a common side effect of prostate cancer treatment, but in clinical practice, it is difficult to predict. Machine learning (ML) models have shown promising results in predicting outcomes, yet the lack of transparency in complex models known as "black-box" has made clinicians wary of relying on them in sensitive decisions. Therefore, finding a balance between accuracy and explainability is crucial for the implementation of ML models. The aim of this study was to employ three different ML classifiers to predict the probability of experiencing UI in men with localized prostate cancer 1-year and 2-year after treatment and compare their accuracy and explainability. METHODS: We used the ProZIB dataset from the Netherlands Comprehensive Cancer Organization (Integraal Kankercentrum Nederland; IKNL) which contained clinical, demographic, and PROM data of 964 patients from 65 Dutch hospitals. Logistic Regression (LR), Random Forest (RF), and Support Vector Machine (SVM) algorithms were applied to predict (in)continence after prostate cancer treatment. RESULTS: All models have been externally validated according to the TRIPOD Type 3 guidelines and their performance was assessed by accuracy, sensitivity, specificity, and AUC. While all three models demonstrated similar performance, LR showed slightly better accuracy than RF and SVM in predicting the risk of UI one year after prostate cancer treatment, achieving an accuracy of 0.75, a sensitivity of 0.82, and an AUC of 0.79. All models for the 2-year outcome performed poorly in the validation set, with an accuracy of 0.6 for LR, 0.65 for RF, and 0.54 for SVM. CONCLUSION: The outcomes of our study demonstrate the promise of using non-black box models, such as LR, to assist clinicians in recognizing high-risk patients and making informed treatment choices. The coefficients of the LR model show the importance of each feature in predicting results, and the generated nomogram provides an acce
- Published
- 2023
17. Adherence to lifestyle recommendations after non-muscle invasive bladder cancer diagnosis and risk of recurrence.
- Author
-
Zutphen, M. van, Hof, J.P., Aben, K.K.H., Kampman, E., Witjes, J.A., Kiemeney, L.A.L.M., Vrieling, A., Zutphen, M. van, Hof, J.P., Aben, K.K.H., Kampman, E., Witjes, J.A., Kiemeney, L.A.L.M., and Vrieling, A.
- Abstract
01 april 2023, Item does not contain fulltext, BACKGROUND: Patients with non-muscle invasive bladder cancer (NMIBC) are at a high risk of tumor recurrence. It has not been previously investigated if adherence to cancer prevention recommendations lowers the risk of recurrence. OBJECTIVES: We examined whether the standardized lifestyle score measuring adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) cancer prevention recommendations was associated with the risk of recurrence and progression among patients with NMIBC. METHODS: The study population included patients diagnosed with primary NMIBC between 2014 and 2017 from the prospective cohort UroLife. Lifestyle was assessed at baseline (n = 979; reflecting the prediagnosis period) and 3-mo postdiagnosis (n = 885). The standardized 2018 WCRF/AICR score was constructed based on recommendations for body weight, physical activity, diet, and alcohol intake. We computed multivariable-adjusted HRs and 95% CIs using Cox proportional hazard regression models. RESULTS: During a median follow-up time of 3.7 y, 320 patients developed ≥1 recurrence(s) and 49 experienced progression. Patients in the highest compared with the lowest tertile of postdiagnosis WCRF/AICR scores had a lower risk of first bladder cancer recurrence (HR: 0.74; 95% CI: 0.56, 0.98). No associations were observed for multiple recurrences (HR: 0.90; 95% CI: 0.70, 1.15) or for the baseline score with either first (HR: 1.07; 95% CI: 0.82, 1.40) or multiple recurrences (HR: 1.04; 95% CI: 0.82, 1.31). Improving lifestyle after diagnosis (per 1-point increase) was not significantly associated with the risk of first or multiple recurrence(s) (HR: 0.87; 95% CI: 0.74, 1.02; HR: 0.93; 95% CI: 0.80, 1.08, respectively). No associations were observed for bladder cancer progression, but the power was limited. CONCLUSIONS: Better adherence to the WCRF/AICR cancer prevention recommendations 3 mo after NMIBC diagnosis, but not before diagnosis, is associated with a decreas
- Published
- 2023
18. Candidate pathway analysis of surfactant proteins identifies CTSH and SFTA2 that influences lung cancer risk.
- Author
-
Luyapan, J., Bosse, Y., Li, Zhonglin, Xiao, Xiangjun, Rosenberger, A., Hung, R.J., Lam, Stephen, Zienolddiny, S., Liu, Geoffrey, Kiemeney, L.A.L.M., Chen, Chu, McKay, J., Johansson, Mattias, Johansson, Mikael, Tardon, A., Fernandez-Tardon, G., Brennan, P., Field, John K., Davies, M.P., Woll, P.J., Cox, Angela, Taylor, F., Arnold, Susanne M., Lazarus, P., Grankvist, K., Landi, M.T., Christiani, D.C., MacKenzie, Todd A., Amos, C.I., Luyapan, J., Bosse, Y., Li, Zhonglin, Xiao, Xiangjun, Rosenberger, A., Hung, R.J., Lam, Stephen, Zienolddiny, S., Liu, Geoffrey, Kiemeney, L.A.L.M., Chen, Chu, McKay, J., Johansson, Mattias, Johansson, Mikael, Tardon, A., Fernandez-Tardon, G., Brennan, P., Field, John K., Davies, M.P., Woll, P.J., Cox, Angela, Taylor, F., Arnold, Susanne M., Lazarus, P., Grankvist, K., Landi, M.T., Christiani, D.C., MacKenzie, Todd A., and Amos, C.I.
- Abstract
Contains fulltext : 296347.pdf (Publisher’s version ) (Closed access)
- Published
- 2023
19. Genetic insights into resting heart rate and its role in cardiovascular disease.
- Author
-
Vegte, Y.J. van de, Eppinga, R.N., Ende, M.Y. van der, Hagemeijer, Y.P., Mahendran, Y., Salfati, E., Smith, A.V., Tan, V.Y., Arking, D.E., Ntalla, I., Appel, E.V., Schurmann, C., Brody, J.A., Rueedi, R., Polasek, O., Sveinbjornsson, G., Lecoeur, C., Ladenvall, C., Zhao, J.H., Isaacs, A., Wang, L., Luan, Jian'an, Hwang, S.J., Mononen, N., Auro, K., Jackson, A.U., Bielak, L.F., Zeng, L., Shah, N., Nethander, M., Campbell, A., Rankinen, T., Pechlivanis, S., Qi, L., Zhao, Wei, Rizzi, F., Tanaka, T., Robino, A., Cocca, M., Lange, L., Müller-Nurasyid, M., Roselli, C., Zhang, W, Kleber, M.E., Guo, X., Lin, H.J., Pavani, F., Galesloot, T.E., Noordam, R., Milaneschi, Y., Schraut, K.E., Hoed, M. den, Degenhardt, F., Trompet, S., Berg, M.E. van den, Pistis, G., Tham, Y.C., Weiss, S., Sim, X.S., Li, H.L., Most, P.J. van der, Nolte, I.M., Lyytikäinen, L.P., Said, M.A., Witte, D.R., Iribarren, C., Launer, L., Ring, S.M., Vries, P.S. de, Sever, P., Linneberg, A., Bottinger, E.P., Padmanabhan, S., Psaty, B.M., Sotoodehnia, N., Kolcic, I., Arnar, D.O., Gudbjartsson, D.F., Holm, H., Balkau, B., Silva, C.T., Newton-Cheh, C.H., Nikus, K., Salo, P., Mohlke, K.L., Peyser, P.A., Schunkert, H., Lorentzon, M., Lahti, J., Rao, D.C., Cornelis, M.C., Faul, J.D., Smith, J.A., Stolarz-Skrzypek, K., Bandinelli, S., Concas, M.P., Sinagra, G., Meitinger, T., Waldenberger, M., Sinner, M.F., Strauch, K., Delgado, G.E., Taylor, K.D., Yao, J., Foco, L., Melander, O., Graaf, J. de, Mutsert, R. de, Geus, E.J.C. de, Johansson, Å., Joshi, P.K., Lind, L., Franke, A., Macfarlane, P.W., Tarasov, K.V., Tan, N., Felix, S.B., Tai, E.S., Quek, D.Q., Snieder, H., Ormel, J., Ingelsson, M., Lindgren, C., Morris, A.P., Raitakari, O.T., Hansen, T., Assimes, T., Gudnason, V., Timpson, N.J., Morrison, A.C., Munroe, P.B., Strachan, D.P., Grarup, N., Loos, R.J.F., Heckbert, S.R., Vollenweider, P., Hayward, C., Stefansson, K., Froguel, P., Groop, L., Wareham, N.J., Duijn, C.M. van, Feitosa, M.F., O'Donnell, C.J., Kähönen, M., Perola, M., Boehnke, M., Kardia, S.L.R., Erdmann, J., Palmer, C.N.A., Ohlsson, C., Porteous, D.J., Eriksson, J.G., Bouchard, C., Moebus, S., Kraft, P., Weir, D.R., Cusi, D., Ferrucci, L., Ulivi, S., Girotto, G., Correa, A., Kääb, S., Peters, A., Chambers, J.C., Kooner, J.S., März, W., Rotter, J.I., Hicks, A.A., Smith, J.G., Kiemeney, L.A.L.M., Mook-Kanamori, D.O., Penninx, B.W.J.H., Gyllensten, U., Wilson, J.F., Burgess, S., Sundström, J., Lieb, W., Jukema, J.W., Eijgelsheim, M., Lakatta, E.L.M., Cheng, C.Y., Dörr, M., Wong, T.Y., Sabanayagam, C., Oldehinkel, A.J., Riese, H., Lehtimäki, T., Verweij, N., Harst, P. van der, Vegte, Y.J. van de, Eppinga, R.N., Ende, M.Y. van der, Hagemeijer, Y.P., Mahendran, Y., Salfati, E., Smith, A.V., Tan, V.Y., Arking, D.E., Ntalla, I., Appel, E.V., Schurmann, C., Brody, J.A., Rueedi, R., Polasek, O., Sveinbjornsson, G., Lecoeur, C., Ladenvall, C., Zhao, J.H., Isaacs, A., Wang, L., Luan, Jian'an, Hwang, S.J., Mononen, N., Auro, K., Jackson, A.U., Bielak, L.F., Zeng, L., Shah, N., Nethander, M., Campbell, A., Rankinen, T., Pechlivanis, S., Qi, L., Zhao, Wei, Rizzi, F., Tanaka, T., Robino, A., Cocca, M., Lange, L., Müller-Nurasyid, M., Roselli, C., Zhang, W, Kleber, M.E., Guo, X., Lin, H.J., Pavani, F., Galesloot, T.E., Noordam, R., Milaneschi, Y., Schraut, K.E., Hoed, M. den, Degenhardt, F., Trompet, S., Berg, M.E. van den, Pistis, G., Tham, Y.C., Weiss, S., Sim, X.S., Li, H.L., Most, P.J. van der, Nolte, I.M., Lyytikäinen, L.P., Said, M.A., Witte, D.R., Iribarren, C., Launer, L., Ring, S.M., Vries, P.S. de, Sever, P., Linneberg, A., Bottinger, E.P., Padmanabhan, S., Psaty, B.M., Sotoodehnia, N., Kolcic, I., Arnar, D.O., Gudbjartsson, D.F., Holm, H., Balkau, B., Silva, C.T., Newton-Cheh, C.H., Nikus, K., Salo, P., Mohlke, K.L., Peyser, P.A., Schunkert, H., Lorentzon, M., Lahti, J., Rao, D.C., Cornelis, M.C., Faul, J.D., Smith, J.A., Stolarz-Skrzypek, K., Bandinelli, S., Concas, M.P., Sinagra, G., Meitinger, T., Waldenberger, M., Sinner, M.F., Strauch, K., Delgado, G.E., Taylor, K.D., Yao, J., Foco, L., Melander, O., Graaf, J. de, Mutsert, R. de, Geus, E.J.C. de, Johansson, Å., Joshi, P.K., Lind, L., Franke, A., Macfarlane, P.W., Tarasov, K.V., Tan, N., Felix, S.B., Tai, E.S., Quek, D.Q., Snieder, H., Ormel, J., Ingelsson, M., Lindgren, C., Morris, A.P., Raitakari, O.T., Hansen, T., Assimes, T., Gudnason, V., Timpson, N.J., Morrison, A.C., Munroe, P.B., Strachan, D.P., Grarup, N., Loos, R.J.F., Heckbert, S.R., Vollenweider, P., Hayward, C., Stefansson, K., Froguel, P., Groop, L., Wareham, N.J., Duijn, C.M. van, Feitosa, M.F., O'Donnell, C.J., Kähönen, M., Perola, M., Boehnke, M., Kardia, S.L.R., Erdmann, J., Palmer, C.N.A., Ohlsson, C., Porteous, D.J., Eriksson, J.G., Bouchard, C., Moebus, S., Kraft, P., Weir, D.R., Cusi, D., Ferrucci, L., Ulivi, S., Girotto, G., Correa, A., Kääb, S., Peters, A., Chambers, J.C., Kooner, J.S., März, W., Rotter, J.I., Hicks, A.A., Smith, J.G., Kiemeney, L.A.L.M., Mook-Kanamori, D.O., Penninx, B.W.J.H., Gyllensten, U., Wilson, J.F., Burgess, S., Sundström, J., Lieb, W., Jukema, J.W., Eijgelsheim, M., Lakatta, E.L.M., Cheng, C.Y., Dörr, M., Wong, T.Y., Sabanayagam, C., Oldehinkel, A.J., Riese, H., Lehtimäki, T., Verweij, N., and Harst, P. van der
- Abstract
Contains fulltext : 296013.pdf (Publisher’s version ) (Open Access), Resting heart rate is associated with cardiovascular diseases and mortality in observational and Mendelian randomization studies. The aims of this study are to extend the number of resting heart rate associated genetic variants and to obtain further insights in resting heart rate biology and its clinical consequences. A genome-wide meta-analysis of 100 studies in up to 835,465 individuals reveals 493 independent genetic variants in 352 loci, including 68 genetic variants outside previously identified resting heart rate associated loci. We prioritize 670 genes and in silico annotations point to their enrichment in cardiomyocytes and provide insights in their ECG signature. Two-sample Mendelian randomization analyses indicate that higher genetically predicted resting heart rate increases risk of dilated cardiomyopathy, but decreases risk of developing atrial fibrillation, ischemic stroke, and cardio-embolic stroke. We do not find evidence for a linear or non-linear genetic association between resting heart rate and all-cause mortality in contrast to our previous Mendelian randomization study. Systematic alteration of key differences between the current and previous Mendelian randomization study indicates that the most likely cause of the discrepancy between these studies arises from false positive findings in previous one-sample MR analyses caused by weak-instrument bias at lower P-value thresholds. The results extend our understanding of resting heart rate biology and give additional insights in its role in cardiovascular disease development.
- Published
- 2023
20. Staging fluorodeoxyglucose positron emission tomography/computed tomography for muscle-invasive bladder cancer: a nationwide population-based study.
- Author
-
Richters, A., Ginkel, N. van, Meijer, R.P., Wondergem, M., Schoots, I., Vis, A.N., Kiemeney, L.A.L.M., Rhijn, B.W.G. van, Witjes, J.A., Aben, K.K.H., Mertens, L.S., Richters, A., Ginkel, N. van, Meijer, R.P., Wondergem, M., Schoots, I., Vis, A.N., Kiemeney, L.A.L.M., Rhijn, B.W.G. van, Witjes, J.A., Aben, K.K.H., and Mertens, L.S.
- Abstract
Item does not contain fulltext, OBJECTIVE: To provide insight into the use and staging information on lymph-node involvement added by fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in patients with muscle-invasive bladder cancer (MIBC), based on a nationwide population-based cohort study. PATIENTS AND METHODS: We analysed a nationwide cohort of patients with MIBC without signs of distant metastases, newly diagnosed in the Netherlands between November 2017 and October 2019. From this cohort, we selected patients who underwent pre-treatment staging with CT only or CT and FDG-PET/CT. The distribution of patients, disease characteristics, imaging findings, nodal status (clinical nodal stage cN0 vs cN+) and treatment were described for each imaging modality group (CT only vs CT and FDG-PET/CT). RESULTS: We identified 2731 patients with MIBC: 1888 (69.1%) underwent CT only; 606 (22.2%) underwent CT and FDG-PET/CT, 237 (8.6%) underwent no CT. Of the patients who underwent CT only, 200/1888 (10.6%) were staged as cN+, vs 217/606 (35.8%) who underwent CT and FDG-PET/CT. Stratified analysis showed that this difference was found in patients with clinical tumour stage (cT)2 as well as cT3/4 MIBC. Of patients who underwent both imaging modalities and were staged with CT as cN0, 109/498 (21.9%) were upstaged to cN+ based on FDG-PET/CT. Radical cystectomy (RC) was the most common treatment within both imaging groups. Preoperative chemotherapy was more frequently applied in cN+ disease and in FDG-PET/CT-staged patients. Concordance of pathological N stage after upfront RC was higher among patients staged as cN+ with CT and FDG-PET/CT (50.0% pN+) than those staged as cN+ with only CT (39.3%). CONCLUSION: Patients with MIBC who underwent pre-treatment staging with FDG-PET/CT were more often staged as lymph node positive, regardless of cT stage. In patients with MIBC who underwent CT and FDG-PET/CT, FDG-PET/CT led to clinical nodal upstaging in approximately one-fifth. Additional im
- Published
- 2023
21. Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum
- Author
-
Beijert, I.J., Hentschel, A.E., Bründl, J., Compérat, E.M., Plass, K., Rodríguez, O., Subiela Henríquez, J.D., Hernández, V., Peña, E. de la, Alemany, I., Turturica, D., Pisano, F., Soria, F., Čapoun, O., Bauerová, L., Pešl, M., Bruins, H.M., Runneboom, W., Herdegen, S., Breyer, J., Brisuda, A., Calatrava, A., Rubio-Briones, J., Seles, M., Mannweiler, S., Bosschieter, J., Kusuma, V.R.M., Ashabere, D., Huebner, N., Cotte, J., Mertens, L.S., Claps, F., Masson-Lecomte, A., Liedberg, F., Cohen, D., Lunelli, L., Cussenot, O., Sheikh, S., Volanis, D., Côté, J.F., Rouprêt, M., Haitel, A., Shariat, S.F., Mostafid, A.H., Nieuwenhuijzen, J.A., Zigeuner, R., Dominguez-Escrig, J.L., Hacek, J., Zlotta, A.R., Burger, M., Evert, M., Hulsbergen-van de Kaa, C.A., Heijden, A.G. van der, Kiemeney, L.A.L.M., Soukup, V., Molinaro, L., Gontero, P., Llorente, C., Algaba, F., Palou, J., N'Dow, J., Ribal, M.J., Kwast, T.H. van der, Babjuk, M., Sylvester, R.J., Rhijn, B.W.G. van, Beijert, I.J., Hentschel, A.E., Bründl, J., Compérat, E.M., Plass, K., Rodríguez, O., Subiela Henríquez, J.D., Hernández, V., Peña, E. de la, Alemany, I., Turturica, D., Pisano, F., Soria, F., Čapoun, O., Bauerová, L., Pešl, M., Bruins, H.M., Runneboom, W., Herdegen, S., Breyer, J., Brisuda, A., Calatrava, A., Rubio-Briones, J., Seles, M., Mannweiler, S., Bosschieter, J., Kusuma, V.R.M., Ashabere, D., Huebner, N., Cotte, J., Mertens, L.S., Claps, F., Masson-Lecomte, A., Liedberg, F., Cohen, D., Lunelli, L., Cussenot, O., Sheikh, S., Volanis, D., Côté, J.F., Rouprêt, M., Haitel, A., Shariat, S.F., Mostafid, A.H., Nieuwenhuijzen, J.A., Zigeuner, R., Dominguez-Escrig, J.L., Hacek, J., Zlotta, A.R., Burger, M., Evert, M., Hulsbergen-van de Kaa, C.A., Heijden, A.G. van der, Kiemeney, L.A.L.M., Soukup, V., Molinaro, L., Gontero, P., Llorente, C., Algaba, F., Palou, J., N'Dow, J., Ribal, M.J., Kwast, T.H. van der, Babjuk, M., Sylvester, R.J., and Rhijn, B.W.G. van
- Abstract
Contains fulltext : 294430.pdf (Publisher’s version ) (Open Access), BACKGROUND: Ta grade 3 (G3) non-muscle-invasive bladder cancer (NMIBC) is a relatively rare diagnosis with an ambiguous character owing to the presence of an aggressive G3 component together with the lower malignant potential of the Ta component. The European Association of Urology (EAU) NMIBC guidelines recently changed the risk stratification for Ta G3 from high risk to intermediate, high, or very high risk. However, prognostic studies on Ta G3 carcinomas are limited and inconclusive. OBJECTIVE: To evaluate the prognostic value of categorizing Ta G3 compared to Ta G2 and T1 G3 carcinomas. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data for 5170 primary Ta-T1 bladder tumors from 17 hospitals were analyzed. Transurethral resection of the tumor was performed between 1990 and 2018. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Time to recurrence and time to progression were analyzed using cumulative incidence functions, log-rank tests, and multivariable Cox-regression models with interaction terms stratified by institution. RESULTS AND LIMITATIONS: Ta G3 represented 7.5% (387/5170) of Ta-T1 carcinomas of which 42% were classified as intermediate risk. Time to recurrence did not differ between Ta G3 and Ta G2 (p = 0.9) or T1 G3 (p = 0.4). Progression at 5 yr occurred for 3.6% (95% confidence interval [CI] 2.7-4.8%) of Ta G2, 13% (95% CI 9.3-17%) of Ta G3, and 20% (95% CI 17-23%) of T1 G3 carcinomas. Time to progression for Ta G3 was shorter than for Ta G2 (p < 0.001) and longer than for T1 G3 (p = 0.002). Patients with Ta G3 NMIBC with concomitant carcinoma in situ (CIS) had worse prognosis and a similar time to progression as for patients with T1 G3 NMIBC with CIS (p = 0.5). Multivariable analyses for recurrence and progression showed similar results. CONCLUSIONS: The prognosis of Ta G3 tumors in terms of progression appears to be in between that of Ta G2 and T1 G3. However, patients with Ta G3 NMIBC with concomitant CIS have worse prognosis that is compar
- Published
- 2023
22. The accuracy of cystoscopy in predicting muscle invasion in newly diagnosed bladder cancer patients.
- Author
-
Straten, C.G.J.I. van, Bruins, M.H., Dijkstra, S, Cornel, E.B., Kortleve, M.D.H., Vocht, T.F. de, Kiemeney, L.A.L.M., Heijden, A.G. van der, Straten, C.G.J.I. van, Bruins, M.H., Dijkstra, S, Cornel, E.B., Kortleve, M.D.H., Vocht, T.F. de, Kiemeney, L.A.L.M., and Heijden, A.G. van der
- Abstract
01 juli 2023, Item does not contain fulltext, PURPOSE: The prognosis of muscle-invasive bladder cancer (MIBC) has not improved for three decades. Transurethral resection of the bladder tumor (TURBT) is the standard procedure for local tumor staging. TURBT has several limitations, including the spread of tumor cells. Therefore, an alternative is needed in patients with suspected MIBC. Recent studies have shown that mpMRI is very accurate in staging bladder tumors. Because the diagnostic efficacy of urethrocystoscopy (UCS) has been reported as good as the efficacy of mpMRI to predict muscle invasion we performed this prospective multicenter study in which we compare UCS with pathology. METHODS: From July 2020 until March 2022, 321 patients with suspected primary BC in seven participating Dutch hospitals were included in this study. A flexible UCS was performed by urologists, physician assistants, or residents. Predictions of muscle invasion using a 5-point Likert scale alongside the histopathology data were recorded. The sensitivity, specificity, predictive values, and 95% confidence intervals were determined using a standard contingency table. RESULTS: Of the 321 included patients, 232 (72.3%) received a histopathological diagnosis of non-muscle-invasive bladder cancer (NMIBC) and 71 (22.1%) were histopathologically diagnosed as MIBC. In 2 patients (0.6%), classification was not possible (Tx). Cystoscopy predicted muscle invasion with a sensitivity of 71.8% (95% CI 59.9-81.9), and a specificity of 89.9% (95% CI 85.4-93.3). This corresponds to a positive predictive value (PPV) of 67.1% and a negative predictive value (NPV) of 91.7%. CONCLUSION: Our study shows a moderate accuracy of cystoscopy to predict muscle invasion. This result does not support the use of cystoscopy only instead of TURBT for local staging.
- Published
- 2023
23. Quality of Life in Patients with High-grade Non-muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guérin Instillations: The EAU-RF NIMBUS Trial.
- Author
-
Straten, C.G.J.I. van, Caris, C., Grimm, M.O., Colombel, M., Muilwijk, T., Martínez-Piñeiro, L., Babjuk, M.M., Türkeri, L.N., Palou, J., Patel, Anup, Bjartell, A.S., Witjes, W.P.J., Heijden, A.G. van der, Kiemeney, L.A.L.M., Straten, C.G.J.I. van, Caris, C., Grimm, M.O., Colombel, M., Muilwijk, T., Martínez-Piñeiro, L., Babjuk, M.M., Türkeri, L.N., Palou, J., Patel, Anup, Bjartell, A.S., Witjes, W.P.J., Heijden, A.G. van der, and Kiemeney, L.A.L.M.
- Abstract
Item does not contain fulltext, BACKGROUND: Adverse events induced by intravesical bacillus Calmette-Guérin (BCG) to treat high-grade non-muscle-invasive bladder cancer (NMIBC) often lead to treatment discontinuation. The EAU-RF NIMBUS trial found a reduced number of standard-dose BCG instillations to be inferior with the standard regimen. Nonetheless, it remains important to evaluate whether patients in the reduced BCG treatment arm had better quality of life (QoL) due to a possible reduction in toxicity or burden. OBJECTIVE: To evaluate whether patients in the EAU-RF NIMBUS trial experienced better QoL after a reduced BCG instillation frequency. DESIGN SETTING AND PARTICIPANTS: A total of 359 patients from 51 European sites were randomized to one of two treatment arms between December 2013 and July 2019. The standard frequency arm (n = 182) was 6 weeks of BCG induction followed by 3 weeks of maintenance at months 3, 6, and 12. The reduced frequency arm (n = 177) was BCG induction at weeks 1, 2, and 6, followed by maintenance instillations at weeks 1 and 3 of months 3, 6, and 12. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Analyses were performed using an intention-to-treat analysis and a per-protocol analysis. QoL was measured using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 version 3.0 (QLQ-C30 v.03) prior to the first and last instillations of each BCG cycle. Group differences were determined using linear regression corrected for QoL at baseline. Differences in QoL over time were tested for significance using a linear mixed model. Side effects were recorded by the treating physician using a standardized form. Chi-square tests were used to compare the side-effect frequency between the arms. RESULTS AND LIMITATIONS: There were no significant differences in the means of each QoL scale between the two arms. There were also no significant changes over time in all QoL domains for both arms. However, differences in the incidence of
- Published
- 2023
24. Body mass index and waist circumference in relation to risk of recurrence and progression after non-muscle invasive bladder cancer.
- Author
-
Zutphen, M. van, Beeren, I., Aben, K.K.H., Heijden, A.G. van der, Witjes, J.A., Kiemeney, L.A.L.M., Vrieling, A., Zutphen, M. van, Beeren, I., Aben, K.K.H., Heijden, A.G. van der, Witjes, J.A., Kiemeney, L.A.L.M., and Vrieling, A.
- Abstract
Contains fulltext : 299848.pdf (Publisher’s version ) (Open Access), BACKGROUND: Obesity may be associated with increased risk of recurrence and progression in patients with non-muscle invasive bladder cancer (NMIBC), but evidence is limited and inconsistent. We examined the associations of body mass index (BMI), waist circumference, and waist-to-hip ratio (WHR) with risk of recurrence and progression among patients with NMIBC. METHODS: This prospective study included 1029 patients diagnosed with primary NMIBC between 2014 and 2017. Patients reported weight 2 years before diagnosis at baseline, and weight, waist and hip circumference at 3 months postdiagnosis. Associations were quantified using Cox proportional hazard analyses, adjusted for clinical and lifestyle characteristics. RESULTS: More than half of patients were overweight (49%) or obese (19%) after diagnosis. During a median follow-up time of 3.6 years, 371 patients developed ≥1 recurrence and 53 experienced progression. No associations with recurrence were observed for BMI (HR(per 5 kg/m2) 0.94; 95% CI 0.82, 1.07), waist circumference (HR(per 10 cm) 0.95; 95% CI 0.86, 1.05), or WHR (HR(per 0.1 unit) 0.90; 95% CI 0.76, 1.06). In contrast, higher BMI was associated with a 40% increased risk of progression, with only the 2-year prediagnosis association reaching statistical significance (HR(per 5 kg/m2) 1.42; 95% CI 1.09, 1.84). No associations for pre-to-postdiagnosis weight change were found. CONCLUSION: General and abdominal obesity were not associated with recurrence risk among patients with NMIBC, but might be associated with increased risk of progression. Studies with sufficient sample size to stratify by tumor stage and treatment are needed to better understand whether and how obesity could influence prognosis.
- Published
- 2023
25. Genetic relationship between the immune system and autism.
- Author
-
Arenella, M., Fanelli, G., Kiemeney, L.A.L.M., McAlonan, G., Murphy, D.G.M., Bralten, J.B., Arenella, M., Fanelli, G., Kiemeney, L.A.L.M., McAlonan, G., Murphy, D.G.M., and Bralten, J.B.
- Abstract
Contains fulltext : 299960.pdf (Publisher’s version ) (Open Access), Autism spectrum disorder (ASD) is a common and complex neurodevelopmental condition. The pathophysiology of ASD is poorly defined; however, it includes a strong genetic component and there is increasing evidence to support a role of immune dysregulation. Nonetheless, it is unclear which immune phenotypes link to ASD through genetics. Hence, we investigated the genetic correlation between ASD and diverse classes of immune conditions and markers; and if these immune-related genetic factors link to specific autistic-like traits in the population. We estimated global and local genetic correlations between ASD (n = 55,420) and 11 immune phenotypes (n = 14,256-755,406) using genome-wide association study summary statistics. Subsequently, polygenic scores (PGS) for these immune phenotypes were calculated in a population-based sample (n = 2487) and associated to five autistic-like traits (i.e., attention to detail, childhood behaviour, imagination, rigidity, social skills), and a total autistic-like traits score. Sex-stratified PGS analyses were also performed. At the genome-wide level, ASD was positively correlated with allergic diseases (ALG), and negatively correlated with lymphocyte count, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE) (FDR-p = 0.01-0.02). At the local genetic level, ASD was correlated with RA, C-reactive protein, and granulocytes and lymphocyte counts (p = 5.8 × 10(-6)-0.002). In the general population sample, increased genetic liability for SLE, RA, ALG, and lymphocyte levels, captured by PGS, was associated with the total autistic score and with rigidity and childhood behaviour (FDR-p = 0.03). In conclusion, we demonstrated a genetic relationship between ASD and immunity that depends on the type of immune phenotype considered; some increase likelihood whereas others may potentially help build resilience. Also, this relationship may be restricted to specific genetic loci and link to specific autistic dimensions (e.g., rigidity)., 01 december 2023
- Published
- 2023
26. Bladder cancer care in the Netherlands. Guidelines and practice: are they in harmony?
- Author
-
Kiemeney, L.A.L.M., Witjes, J.A., Aben, K.K.H., Meijer, Richard P., Hoogstraten, L.M.C. van, Kiemeney, L.A.L.M., Witjes, J.A., Aben, K.K.H., Meijer, Richard P., and Hoogstraten, L.M.C. van
- Abstract
Contains fulltext : 299213.pdf (Publisher’s version ) (Closed access), Over the last decades, survival rates for bladder cancer have barely improved. Improving bladder cancer care can improve patient outcomes such as survival. In order to do so, we need more insight into bladder cancer care. By assessing variation in guideline adherence regarding specific aspects of bladder cancer care between hospitals in the Netherlands, identifying underlying factors, and/or assessing the effect of this variation on patient outcomes, we created a solid foundation for evidence-based recommendations to improve bladder cancer care. The research in this thesis revealed substantial variation in current bladder cancer care. In specific aspects of bladder cancer care, this variation appeared to affect patient outcomes such as survival. Recommendations were formulated to improve bladder cancer care, with the ultimate goal of providing the best care possible for patients with bladder cancer., Radboud University, 19 december 2023, Promotores : Kiemeney, L.A.L.M., Witjes, J.A. Co-promotores : Aben, K.K.H., Meijer, Richard P., 207 p.
- Published
- 2023
27. The association of body composition with postoperative complications and length of hospital stay after radical or partial nephrectomy in patients with renal cell cancer: a multicenter population-based cohort study
- Author
-
Maurits, J.S.F., Sedelaar, J.P.M., Aben, K.K.H., Kiemeney, L.A.L.M., and Vrieling, A.
- Subjects
Reproductive Medicine ,Urological cancers Radboud Institute for Health Sciences [Radboudumc 15] ,Urology ,Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15] - Abstract
Contains fulltext : 287907.pdf (Publisher’s version ) (Closed access)
- Published
- 2022
28. Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy
- Author
-
Hoogstraten, L.M.C. van, Gennep, E.J. van, Kiemeney, L.A.L.M., Witjes, J.A., Voskuilen, C.S., Deelen, M., Mertens, L.S., Meijer, R.P., Boormans, J.L., Robbrecht, D.G.J., Beerepoot, L.V., Verhoeven, R.H.A., Ripping, T.M., Rhijn, B.W.G. van, Aben, K.K.H., Hermans, T.J.N., BlaZIB Study Grp, Oncology, CCA - Cancer Treatment and Quality of Life, Cancer Center Amsterdam, APH - Methodology, APH - Quality of Care, MUMC+: MA AIOS Urologie (9), RS: FHML non-thematic output, Urology, Internal medicine, and Medical Oncology
- Subjects
medicine.medical_specialty ,Neoplasm, Residual ,IMPACT ,PET/CT ,Urology ,medicine.medical_treatment ,Cystectomy ,Gastroenterology ,Neoadjuvant chemotherapy ,SDG 3 - Good Health and Well-being ,Downstaging ,Internal medicine ,Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15] ,MANAGEMENT ,Humans ,Medicine ,Neoplasm Invasiveness ,Prospective Studies ,DISSECTION ,Lymph node ,TRANSURETHRAL RESECTION ,Aged ,Netherlands ,Retrospective Studies ,Carcinoma, Transitional Cell ,Bladder cancer ,business.industry ,Cancer ,medicine.disease ,Occult ,Primary tumor ,Neoadjuvant Therapy ,Cancer registry ,Radical cystectomy ,medicine.anatomical_structure ,Urinary Bladder Neoplasms ,Lymphatic Metastasis ,Urological cancers Radboud Institute for Health Sciences [Radboudumc 15] ,Cohort ,business ,Lymph node metastases - Abstract
Purpose Little is known about the prevalence of occult lymph node metastases (LNM) in muscle-invasive bladder cancer (MIBC) patients with pathological downstaging of the primary tumor. We aimed to estimate the prevalence of occult LNM in patients without residual MIBC at radical cystectomy (RC) with or without neoadjuvant chemotherapy (NAC) or neoadjuvant radiotherapy (NAR), and to assess overall survival (OS). Methods Patients with cT2-T4aN0M0 urothelial MIBC who underwent RC plus pelvic lymph node dissection (PLND) with curative intent between January 1995–December 2013 (retrospective Netherlands Cancer Registry (NCR) cohort) and November 2017–October 2019 (prospective NCR-BlaZIB cohort (acronym in Dutch: BlaaskankerZorg In Beeld; in English: Insight into bladder cancer care)) were identified from the nationwide NCR. The prevalence of occult LNM was calculated and OS of patients with y)pT2N0 vs. y)pT2N+ disease was estimated by the Kaplan–Meier method. Results In total, 4657 patients from the NCR cohort and 760 patients from the NCR-BlaZIB cohort were included. Of 1374 patients downstaged to y)pT2, 4.3% (N = 59) had occult LNM 4.1% (N = 49) of patients with cT2-disease and 5.6% (N = 10) with cT3-4a-disease. This was 4.0% (N = 44) in patients without NAC or NAR, 4.5% (N = 10) in patients with NAC, and 13.5% (N = 5) in patients with NAR but number of patients treated with NAR and downstaged disease was small. The prevalence of y)pT2N+ disease was 4.2% (N = 48) in the NCR cohort and 4.6% (N = 11) in the NCR-BlaZIB cohort. For patients with y)pT2N+ and y)pT2N0, median OS was 3.5 years (95% CI 2.5–8.9) versus 12.9 years (95% CI 11.7–14.0), respectively. Conclusion Occult LNM were found in 4.3% of patients with cT2-4aN0M0 MIBC with (near-) complete downstaging of the primary tumor following RC plus PLND. This was regardless of NAC or clinical T-stage. Patients with occult LNM showed considerable worse survival. These results can help in counseling patients for bladder-sparing treatments.
- Published
- 2022
29. Prognosis of primary papillary Ta-G3 bladder cancer in the non-muscle invasive spectrum
- Author
-
Beijert, I.J., primary, Hentschel, A.E., additional, Bründl, J., additional, Compérat, E.M, additional, Plass, K., additional, Rodríguez, O., additional, Subiela Henríquez, J.D., additional, Hernández, V., additional, De La Peña, E., additional, Alemany, I., additional, Turturica, D., additional, Pisano, F., additional, Soria, F., additional, Čapoun, O., additional, Bauerová, L., additional, Pešl, M., additional, Bruins, H.M., additional, Runneboom, W., additional, Herdegen, S., additional, Breyer, J., additional, Brisuda, A., additional, Calatrava, A., additional, Rubio-Briones, J.., additional, Seles, M., additional, Mannweiler, S., additional, Bosschieter, J., additional, Kusuma, V.R.M., additional, Ashabere, D., additional, Huebner, N., additional, Cotte, J., additional, Mertens, L.S, additional, Masson-Lecomte, A., additional, Liedberg, F., additional, Cohen, D., additional, Lunelli, L., additional, Cussenot, O., additional, El Sheikh, S., additional, Volanis, D., additional, Côté, J., additional, Rouprêt, M., additional, Haitel, A., additional, Shariat, S.F., additional, Mostafid, A.H., additional, Nieuwenhuijzen, J.A., additional, Zigeuner, R., additional, Dominguez-Escrig, J.L., additional, Hacek, J., additional, Zlotta, A.R., additional, Burger, M., additional, Evert, M., additional, Hulsbergen - Van De Kaa, C.A., additional, Van Der Heijden, A.G., additional, Kiemeney, L.A.L.M., additional, Soukup, V., additional, Molinaro, L., additional, Gontero, P., additional, Llorente, C., additional, Algaba, F., additional, Palou, J., additional, N’Dow, J., additional, Ribal, M.J., additional, Van Der Kwast, T.H., additional, Babjuk, M., additional, Sylvester, R.J., additional, and Van Rhijn, B.W.G., additional
- Published
- 2022
- Full Text
- View/download PDF
30. O3 - Prognosis of primary papillary Ta-G3 bladder cancer in the non-muscle invasive spectrum
- Author
-
Beijert, I.J., Hentschel, A.E., Bründl, J., Compérat, E.M, Plass, K., Rodríguez, O., Subiela Henríquez, J.D., Hernández, V., De La Peña, E., Alemany, I., Turturica, D., Pisano, F., Soria, F., Čapoun, O., Bauerová, L., Pešl, M., Bruins, H.M., Runneboom, W., Herdegen, S., Breyer, J., Brisuda, A., Calatrava, A., Rubio-Briones, J.., Seles, M., Mannweiler, S., Bosschieter, J., Kusuma, V.R.M., Ashabere, D., Huebner, N., Cotte, J., Mertens, L.S, Masson-Lecomte, A., Liedberg, F., Cohen, D., Lunelli, L., Cussenot, O., El Sheikh, S., Volanis, D., Côté, J., Rouprêt, M., Haitel, A., Shariat, S.F., Mostafid, A.H., Nieuwenhuijzen, J.A., Zigeuner, R., Dominguez-Escrig, J.L., Hacek, J., Zlotta, A.R., Burger, M., Evert, M., Hulsbergen - Van De Kaa, C.A., Van Der Heijden, A.G., Kiemeney, L.A.L.M., Soukup, V., Molinaro, L., Gontero, P., Llorente, C., Algaba, F., Palou, J., N’Dow, J., Ribal, M.J., Van Der Kwast, T.H., Babjuk, M., Sylvester, R.J., and Van Rhijn, B.W.G.
- Published
- 2022
- Full Text
- View/download PDF
31. Wanneer is onderzoek nodig bij prostaatkanker in de familie?
- Author
-
Cremers, R., Blanker, M., Asperen, C. van, Bloemendal, M., Bangma, C., and Kiemeney, L.A.L.M.
- Subjects
Urological cancers Radboud Institute for Health Sciences [Radboudumc 15] - Abstract
Item does not contain fulltext
- Published
- 2021
32. Skeletal muscle radiodensity and visceral adipose tissue index are associated with survival in renal cell cancer - A multicenter population-based cohort study
- Author
-
Maurits, J.S.F., Sedelaar, J.P.M., Mulders, P.F.A., Aben, K.K.H., Kiemeney, L.A.L.M., Vrieling, A., Maurits, J.S.F., Sedelaar, J.P.M., Mulders, P.F.A., Aben, K.K.H., Kiemeney, L.A.L.M., and Vrieling, A.
- Abstract
Item does not contain fulltext, INTRODUCTION: Body composition has been associated with disease outcome in several cancer types. Results for localized and metastatic renal cell cancer (RCC) are limited and inconsistent. Our aim was to examine the association between body composition and survival in RCC. METHODS: We conducted a population-based historical cohort study including patients diagnosed with RCC from 2008 to 2012. Diagnostic Computed Tomography images at the third lumbar vertebra (L3) were assessed for skeletal muscle index (SMI), skeletal muscle density (SMD), visceral adipose tissue index (VATI) and subcutaneous adipose tissue index (SATI). Clinical data was retrieved from medical records. Multivariable Cox regressions with restricted cubic splines were used to determine hazard ratios (HRs) and 95% confidence intervals (95%CIs) for 10-unit increases in body composition features with overall survival (OS) and recurrence-free survival (RFS). RESULTS: We included 719 stage I-III (of whom 254 (35.3%) died and 148 (21.9%) experienced recurrence) and 320 stage IV RCC patients (of whom 298 (93.1%) died). Median follow-up was 6.35 years (interquartile range; 1.41-8.23). For stage I-III, higher SMD was associated with better OS (men: HR 0.86; 95% CI 0.68-1.08; women: HR 0.69; 95% CI 0.50-0.95). Lower compared to median VATI was associated with worse OS for both men (HR 1.38; 95%CI 1.05-1.83 for VATI = 25) and women (HR 1.67; 95%CI 1.01-2.78 for VATI = 20). For stage IV, higher SMD and higher VATI were associated with better OS among men (HR 0.74; 95% CI 0.59-0.94 and HR 0.93; 95% CI 0.88-0.99, respectively). Results for women were similar but non-significant. No statistically significant associations were found for SMI or SATI. CONCLUSION: Higher SMD and higher VATI were marginally associated with better survival in RCC patients and might be useful for better prognostication. However, the added value to current prognostic scores needs to be investigated.
- Published
- 2022
33. Gene-gene interaction of AhRwith and within the Wntcascade affects susceptibility to lung cancer
- Author
-
Rosenberger, A., Muttray, Nils, Hung, R.J., Christiani, David C., Caporaso, Neil E., Liu, Geoffrey, Kiemeney, L.A.L.M., Amos, C.I., Bickeböller, H., Rosenberger, A., Muttray, Nils, Hung, R.J., Christiani, David C., Caporaso, Neil E., Liu, Geoffrey, Kiemeney, L.A.L.M., Amos, C.I., and Bickeböller, H.
- Abstract
Item does not contain fulltext
- Published
- 2022
34. Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-muscle-invasive Bladder Cancer
- Author
-
Galesloot, T.E., Grotenhuis, A.J., Kolev, D.R., Aben, K.K.H., Bryan, R.T., Catto, J.W., Cheng, K.K., Conroy, S., Dyrskjøt, L., Fleshner, N.E., James, N.D., Lamy, P., Lindskrog, S.V., Malats, N., Mengual, L., Verhaegh, G.W., Zeegers, M.P., Kiemeney, L.A.L.M., Vermeulen, S.H., Galesloot, T.E., Grotenhuis, A.J., Kolev, D.R., Aben, K.K.H., Bryan, R.T., Catto, J.W., Cheng, K.K., Conroy, S., Dyrskjøt, L., Fleshner, N.E., James, N.D., Lamy, P., Lindskrog, S.V., Malats, N., Mengual, L., Verhaegh, G.W., Zeegers, M.P., Kiemeney, L.A.L.M., and Vermeulen, S.H.
- Abstract
Contains fulltext : 248271.pdf (Publisher’s version ) (Open Access), BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) is characterized by frequent recurrences and a risk of progression in stage and grade. Increased knowledge of underlying biological mechanisms is needed. OBJECTIVE: To identify single nucleotide polymorphisms (SNPs) associated with recurrence-free (RFS) and progression-free (PFS) survival in NMIBC. DESIGN, SETTING, AND PARTICIPANTS: We analyzed outcome data from 3400 newly diagnosed NMIBC patients from the Netherlands, the UK, Canada, and Spain. We generated genome-wide germline SNP data using Illumina OmniExpress and Infinium Global Screening Array in combination with genotype imputation. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cohort-specific genome-wide association studies (GWASs) for RFS and PFS were performed using a Cox proportional hazard model. Results were combined in a fixed-effect inverse-variance weighted meta-analysis. Candidate genes for the identified SNP associations were prioritized using functional annotation, gene-based analysis, expression quantitative trait locus analysis, and transcription factor binding site databases. Tumor expression levels of prioritized genes were tested for association with RFS and PFS in an independent NMIBC cohort. RESULTS AND LIMITATIONS: This meta-analysis revealed a genome-wide significant locus for RFS on chromosome 14 (lead SNP rs12885353, hazard ratio [HR] C vs T allele 1.55, 95% confidence interval [CI] 1.33-1.82, p = 4.0 × 10(-8)), containing genes G2E3 and SCFD1. Higher expression of SCFD1 was associated with increased RFS (HR 0.70, 95% CI 0.59-0.84, p(FDR) = 0.003). Twelve other loci were suggestively associated with RFS (p < 10(-5)), pointing toward 18 additional candidate genes. For PFS, ten loci showed suggestive evidence of association, indicating 36 candidate genes. Expression levels of ten of these genes were statistically significantly associated with PFS, of which four (IFT140, UBE2I, FAHD1, and NME3) showed directional consistency with our
- Published
- 2022
35. Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients
- Author
-
Hoogstraten, L.M.C. van, Gennep, E.J. van, Kiemeney, L.A.L.M., Witjes, J.A., Voskuilen, C.S., Deelen, M., Mertens, L.S., Meijer, R.P., Boormans, J.L., Robbrecht, D.G.J., Beerepoot, L.V., Verhoeven, R.H.A., Ripping, T.M., Rhijn, B.W. van, Aben, K.K.H., Hermans, T.J., Hoogstraten, L.M.C. van, Gennep, E.J. van, Kiemeney, L.A.L.M., Witjes, J.A., Voskuilen, C.S., Deelen, M., Mertens, L.S., Meijer, R.P., Boormans, J.L., Robbrecht, D.G.J., Beerepoot, L.V., Verhoeven, R.H.A., Ripping, T.M., Rhijn, B.W. van, Aben, K.K.H., and Hermans, T.J.
- Abstract
Item does not contain fulltext, PURPOSE: Little is known about the prevalence of occult lymph node metastases (LNM) in muscle-invasive bladder cancer (MIBC) patients with pathological downstaging of the primary tumor. We aimed to estimate the prevalence of occult LNM in patients without residual MIBC at radical cystectomy (RC) with or without neoadjuvant chemotherapy (NAC) or neoadjuvant radiotherapy (NAR), and to assess overall survival (OS). METHODS: Patients with cT2-T4aN0M0 urothelial MIBC who underwent RC plus pelvic lymph node dissection (PLND) with curative intent between January 1995-December 2013 (retrospective Netherlands Cancer Registry (NCR) cohort) and November 2017-October 2019 (prospective NCR-BlaZIB cohort (acronym in Dutch: BlaaskankerZorg In Beeld; in English: Insight into bladder cancer care)) were identified from the nationwide NCR. The prevalence of occult LNM was calculated and OS of patients with <(y)pT2N0 vs. <(y)pT2N+ disease was estimated by the Kaplan-Meier method. RESULTS: In total, 4657 patients from the NCR cohort and 760 patients from the NCR-BlaZIB cohort were included. Of 1374 patients downstaged to <(y)pT2, 4.3% (N = 59) had occult LNM 4.1% (N = 49) of patients with cT2-disease and 5.6% (N = 10) with cT3-4a-disease. This was 4.0% (N = 44) in patients without NAC or NAR, 4.5% (N = 10) in patients with NAC, and 13.5% (N = 5) in patients with NAR but number of patients treated with NAR and downstaged disease was small. The prevalence of <(y)pT2N+ disease was 4.2% (N = 48) in the NCR cohort and 4.6% (N = 11) in the NCR-BlaZIB cohort. For patients with <(y)pT2N+ and <(y)pT2N0, median OS was 3.5 years (95% CI 2.5-8.9) versus 12.9 years (95% CI 11.7-14.0), respectively. CONCLUSION: Occult LNM were found in 4.3% of patients with cT2-4aN0M0 MIBC with (near-) complete downstaging of the primary tumor following RC plus PLND. This was regardless of NAC or clinical T-stage. Patients with occult LNM showed considerable worse survival. These results can help in counseling pa
- Published
- 2022
36. Polygenic risk modeling for prediction of epithelial ovarian cancer risk
- Author
-
Dareng, E.O., Tyrer, J.P., Barnes, D.R., Jones, M.R., Yang, X, Aben, K.K.H., Adank, M.A., Agata, S., Andrulis, I.L., Anton-Culver, H., Antonenkova, N.N., Aravantinos, G., Arun, B.K., Augustinsson, A., Balmaña, J., Bandera, E.V., Barkardottir, R.B., Barrowdale, D., Beckmann, M.W., Beeghly-Fadiel, A., Benitez, J., Bermisheva, M., Bernardini, M.Q., Bjorge, L., Black, A., Bogdanova, N.V., Bonanni, B., Borg, A., Brenton, J.D., Budzilowska, A., Butzow, R., Buys, S.S., Cai, H., Caligo, M.A., Campbell, I., Cannioto, R., Cassingham, H., Chang-Claude, J., Chanock, S.J., Chen, K., Chiew, Y.E., Chung, W.K., Claes, K.B.M., Colonna, S., Cook, L.S., Couch, F.J., Daly, M.B., Dao, F., Davies, E., Hoya, M. de la, Putter, R. de, Dennis, J., DePersia, A., Devilee, P., Diez, O., Ding, Y.C., Doherty, J.A., Domchek, S.M., Dörk, T., Bois, A. du, Dürst, M., Eccles, D.M., Eliassen, H.A., Engel, C., Evans, G.D., Fasching, P.A., Flanagan, J.M., Fortner, R.T., Machackova, E., Friedman, E., Ganz, P.A., Garber, J., Gensini, F., Giles, G.G., Glendon, G., Godwin, A.K., Goodman, M.T., Greene, M.H., Gronwald, J., Hahnen, E., Haiman, C.A., Håkansson, N., Hamann, U., Hansen, T.V., Harris, H.R., Hartman, M, Heitz, F., Hildebrandt, M.A., Høgdall, E., Høgdall, C.K., Hopper, J.L., Huang, R.Y., Huff, C., Hulick, P.J., Huntsman, D.G., Imyanitov, E.N., Isaacs, C., Jakubowska, A., James, P.A., Kiemeney, L.A.L.M., Altena, A.M. van, Janavicius, R., Antoniou, A.C., Pharoah, P.D., Dareng, E.O., Tyrer, J.P., Barnes, D.R., Jones, M.R., Yang, X, Aben, K.K.H., Adank, M.A., Agata, S., Andrulis, I.L., Anton-Culver, H., Antonenkova, N.N., Aravantinos, G., Arun, B.K., Augustinsson, A., Balmaña, J., Bandera, E.V., Barkardottir, R.B., Barrowdale, D., Beckmann, M.W., Beeghly-Fadiel, A., Benitez, J., Bermisheva, M., Bernardini, M.Q., Bjorge, L., Black, A., Bogdanova, N.V., Bonanni, B., Borg, A., Brenton, J.D., Budzilowska, A., Butzow, R., Buys, S.S., Cai, H., Caligo, M.A., Campbell, I., Cannioto, R., Cassingham, H., Chang-Claude, J., Chanock, S.J., Chen, K., Chiew, Y.E., Chung, W.K., Claes, K.B.M., Colonna, S., Cook, L.S., Couch, F.J., Daly, M.B., Dao, F., Davies, E., Hoya, M. de la, Putter, R. de, Dennis, J., DePersia, A., Devilee, P., Diez, O., Ding, Y.C., Doherty, J.A., Domchek, S.M., Dörk, T., Bois, A. du, Dürst, M., Eccles, D.M., Eliassen, H.A., Engel, C., Evans, G.D., Fasching, P.A., Flanagan, J.M., Fortner, R.T., Machackova, E., Friedman, E., Ganz, P.A., Garber, J., Gensini, F., Giles, G.G., Glendon, G., Godwin, A.K., Goodman, M.T., Greene, M.H., Gronwald, J., Hahnen, E., Haiman, C.A., Håkansson, N., Hamann, U., Hansen, T.V., Harris, H.R., Hartman, M, Heitz, F., Hildebrandt, M.A., Høgdall, E., Høgdall, C.K., Hopper, J.L., Huang, R.Y., Huff, C., Hulick, P.J., Huntsman, D.G., Imyanitov, E.N., Isaacs, C., Jakubowska, A., James, P.A., Kiemeney, L.A.L.M., Altena, A.M. van, Janavicius, R., Antoniou, A.C., and Pharoah, P.D.
- Abstract
Item does not contain fulltext, Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard approaches of PRS construction. Here, we implemented computationally efficient, penalized, logistic regression models (lasso, elastic net, stepwise) to individual level genotype data and a Bayesian framework with continuous shrinkage, "select and shrink for summary statistics" (S4), to summary level data for epithelial non-mucinous ovarian cancer risk prediction. We developed the models in a dataset consisting of 23,564 non-mucinous EOC cases and 40,138 controls participating in the Ovarian Cancer Association Consortium (OCAC) and validated the best models in three populations of different ancestries: prospective data from 198,101 women of European ancestries; 7,669 women of East Asian ancestries; 1,072 women of African ancestries, and in 18,915 BRCA1 and 12,337 BRCA2 pathogenic variant carriers of European ancestries. In the external validation data, the model with the strongest association for non-mucinous EOC risk derived from the OCAC model development data was the S4 model (27,240 SNPs) with odds ratios (OR) of 1.38 (95% CI: 1.28-1.48, AUC: 0.588) per unit standard deviation, in women of European ancestries; 1.14 (95% CI: 1.08-1.19, AUC: 0.538) in women of East Asian ancestries; 1.38 (95% CI: 1.21-1.58, AUC: 0.593) in women of African ancestries; hazard ratios of 1.36 (95% CI: 1.29-1.43, AUC: 0.592) in BRCA1 pathogenic variant carriers and 1.49 (95% CI: 1.35-1.64, AUC: 0.624) in BRCA2 pathogenic variant carriers. Incorporation of the S4 PRS in risk prediction models for ovarian cancer may have clinical utility in ovarian cancer prevention programs.
- Published
- 2022
37. Iam hiQ-a novel pair of accuracy indices for imputed genotypes
- Author
-
Rosenberger, A., Tozzi, V., Kiemeney, L.A.L.M., Bickeböller, H., Rosenberger, A., Tozzi, V., Kiemeney, L.A.L.M., and Bickeböller, H.
- Abstract
Contains fulltext : 249824.pdf (Publisher’s version ) (Open Access), BACKGROUND: Imputation of untyped markers is a standard tool in genome-wide association studies to close the gap between directly genotyped and other known DNA variants. However, high accuracy with which genotypes are imputed is fundamental. Several accuracy measures have been proposed and some are implemented in imputation software, unfortunately diversely across platforms. In the present paper, we introduce Iam hiQ, an independent pair of accuracy measures that can be applied to dosage files, the output of all imputation software. Iam (imputation accuracy measure) quantifies the average amount of individual-specific versus population-specific genotype information in a linear manner. hiQ (heterogeneity in quantities of dosages) addresses the inter-individual heterogeneity between dosages of a marker across the sample at hand. RESULTS: Applying both measures to a large case-control sample of the International Lung Cancer Consortium (ILCCO), comprising 27,065 individuals, we found meaningful thresholds for Iam and hiQ suitable to classify markers of poor accuracy. We demonstrate how Manhattan-like plots and moving averages of Iam and hiQ can be useful to identify regions enriched with less accurate imputed markers, whereas these regions would by missed when applying the accuracy measure info (implemented in IMPUTE2). CONCLUSION: We recommend using Iam hiQ additional to other accuracy scores for variant filtering before stepping into the analysis of imputed GWAS data.
- Published
- 2022
38. The Feasibility of Implementing Mainstream Germline Genetic Testing in Routine Cancer Care-A Systematic Review
- Author
-
Bokkers, K., Vlaming, M., Engelhardt, E.G., Zweemer, R.P., Oort, I.M. van, Kiemeney, L.A.L.M., Bleiker, E.M.A., Ausems, M.G.E.M., Bokkers, K., Vlaming, M., Engelhardt, E.G., Zweemer, R.P., Oort, I.M. van, Kiemeney, L.A.L.M., Bleiker, E.M.A., and Ausems, M.G.E.M.
- Abstract
Contains fulltext : 248306.pdf (Publisher’s version ) (Open Access), BACKGROUND: Non-genetic healthcare professionals can provide pre-test counseling and order germline genetic tests themselves, which is called mainstream genetic testing. In this systematic review, we determined whether mainstream genetic testing was feasible in daily practice while maintaining quality of genetic care. METHODS: PubMed, Embase, CINAHL, and PsychINFO were searched for articles describing mainstream genetic testing initiatives in cancer care. RESULTS: Seventeen articles, reporting on 15 studies, met the inclusion criteria. Non-genetic healthcare professionals concluded that mainstream genetic testing was possible within the timeframe of a routine consultation. In 14 studies, non-genetic healthcare professionals completed some form of training about genetics. When referral was coordinated by a genetics team, the majority of patients carrying a pathogenic variant were seen for post-test counseling by genetic healthcare professionals. The number of days between cancer diagnosis and test result disclosure was always lower in the mainstream genetic testing pathway than in the standard genetic testing pathway (e.g., pre-test counseling at genetics department). CONCLUSIONS: Mainstream genetic testing seems feasible in daily practice with no insurmountable barriers. A structured pathway with a training procedure is desirable, as well as a close collaboration between genetics and other clinical departments.
- Published
- 2022
39. Mainstream germline genetic testing in men with metastatic prostate cancer: design and protocol for a multicenter observational study
- Author
-
Vlaming, M., Bleiker, E.M., Oort, I.M. van, Kiemeney, L.A.L.M., Ausems, M.G.E.M., Vlaming, M., Bleiker, E.M., Oort, I.M. van, Kiemeney, L.A.L.M., and Ausems, M.G.E.M.
- Abstract
Contains fulltext : 287587.pdf (Publisher’s version ) (Open Access), BACKGROUND: In international guidelines, germline genetic testing is recommended for patients with metastatic prostate cancer. Before undergoing germline genetic testing, these patients should receive pre-test counseling. In the standard genetic care pathway, pre-test counseling is provided by a healthcare professional of a genetics department. Because the number of patients with metastatic prostate cancer is large, the capacity in the genetics departments might be insufficient. Therefore, we aim to implement so-called mainstream genetic testing in the Netherlands for patients with metastatic prostate cancer. In a mainstream genetic testing pathway, non-genetic healthcare professionals discuss and order germline genetic testing. In our DISCOVER study, we will assess the experiences among patients and non-genetic healthcare professionals with this new pathway. METHODS: A multicenter prospective observational cohort study will be conducted in 15 hospitals, in different regions of the Netherlands. We developed an online training module on genetics in prostate cancer and the counseling of patients. After completion of this module, non-genetic healthcare professionals will provide pre-test counseling and order germline genetic testing in metastatic prostate cancer patients. Both non-genetic healthcare professionals and patients receive three questionnaires. We will determine the experience with mainstream genetic testing, based on satisfaction and acceptability. Patients with a pathogenic germline variant will also be interviewed. We will determine the efficacy of the mainstreaming pathway, based on time investment for non-genetic healthcare professionals and the prevalence of pathogenic germline variants. DISCUSSION: This study is intended to be one of the largest studies on mainstream genetic testing in prostate cancer. The results of this study can improve the mainstream genetic testing pathway in patients with prostate cancer. TRIAL REGISTRATION: The study is registe
- Published
- 2022
40. Overall Survival of Patients Receiving Cisplatin or Carboplatin for Primary Metastatic Urothelial Carcinoma of the Bladder: A Contemporary Dutch Nationwide Cohort Study
- Author
-
Richters, A., Boormans, J.L., Heijden, M.S. van der, Heijden, A.G. van der, Meijer, Richard P., Mehra, N., Kiemeney, L.A.L.M., Aben, K.K.H., Richters, A., Boormans, J.L., Heijden, M.S. van der, Heijden, A.G. van der, Meijer, Richard P., Mehra, N., Kiemeney, L.A.L.M., and Aben, K.K.H.
- Abstract
Contains fulltext : 285302.pdf (Publisher’s version ) (Open Access)
- Published
- 2022
41. The Impact of the COVID-19 Pandemic on Bladder Cancer Care in the Netherlands
- Author
-
Hoogstraten, L.M.C. van, Kiemeney, L.A.L.M., Meijer, Richard P., Leenders, G. van, Vanneste, Ben G.L., Incrocci, Luca, Witjes, J.A., Aben, K.K.H., Hoogstraten, L.M.C. van, Kiemeney, L.A.L.M., Meijer, Richard P., Leenders, G. van, Vanneste, Ben G.L., Incrocci, Luca, Witjes, J.A., and Aben, K.K.H.
- Abstract
Item does not contain fulltext
- Published
- 2022
42. Impact of the COVID-19 outbreak on prostate cancer care in the Netherlands
- Author
-
Deukeren, D.V., Heesterman, B.L., Roelofs, L., Kiemeney, L.A.L.M., Witjes, J.A., Smilde, T.J., Leenders, G. van, Incrocci, L., Vanneste, B.G.L., Meijer, R.P., Siesling, S., Bezooijen, B., Aben, K.K.H., Deukeren, D.V., Heesterman, B.L., Roelofs, L., Kiemeney, L.A.L.M., Witjes, J.A., Smilde, T.J., Leenders, G. van, Incrocci, L., Vanneste, B.G.L., Meijer, R.P., Siesling, S., Bezooijen, B., and Aben, K.K.H.
- Abstract
Contains fulltext : 251728.pdf (Publisher’s version ) (Open Access), INTRODUCTION: The COVID-19 outbreak has affected care for non-COVID diseases like cancer. We evaluated the impact of the COVID-19 outbreak on prostate cancer care in the Netherlands. METHODS: Prostate cancer diagnoses per month in 2020-2021 versus 2018-2019 were compared based on preliminary data of the Netherlands Cancer Registry (NCR) and nationwide pathology network. Detailed data was retrieved from the NCR for the cohorts diagnosed from March-May 2020 (first COVID-19 wave) and March-May 2018-2019 (reference). Changes in number of diagnoses, age, disease stage and first-line treatment were compared. RESULTS: An initial decline of 17% in prostate cancer diagnoses during the first COVID-19 wave was observed. From May onwards the number of diagnoses started to restore to approximately 95% of the expected number by the end of 2020. Stage at diagnosis remainedstable over time. In low-risk localised prostate cancer radical prostatectomy was conducted more often in week 9-12 (21% versus 12% in the reference period; OR=1.9, 95% CI; 1.2-3.1) and less active surveillance was applied (67% versus 78%; OR=0.6, 95% CI; 0.4-0.9). In the intermediate-risk group, a similar change was observed in week 13-16. Radical prostatectomy volumes in 2020 were comparable to 2018-2019. CONCLUSION: During the first COVID-19 wave the number of prostate cancer diagnoses declined. In the second half of 2020 this largely restored although the number remained lower than expected. Changes in treatment were temporary and compliant with adapted guidelines. Although delayed diagnoses could result in a less favourable stage distribution, possibly affecting survival, this seems not very likely.
- Published
- 2022
43. Logical Imputation to Optimize Prognostic Risk Classification in Metastatic Renal Cell Cancer
- Author
-
Maurits, J.S.F., Zanden, L.F.M. van der, Diekstra, M.H.M., Ambert, V., Castellano, D., Garcia-Donas, Jesus, Oosterwijk, E., Kiemeney, L.A.L.M., Vermeulen, S.H., Maurits, J.S.F., Zanden, L.F.M. van der, Diekstra, M.H.M., Ambert, V., Castellano, D., Garcia-Donas, Jesus, Oosterwijk, E., Kiemeney, L.A.L.M., and Vermeulen, S.H.
- Abstract
Contains fulltext : 286069.pdf (Publisher’s version ) (Open Access)
- Published
- 2022
44. A Large-Scale Genome-Wide Gene-Gene Interaction Study of Lung Cancer Susceptibility in Europeans With a Trans-Ethnic Validation in Asians
- Author
-
Zhang, Ruyang, Shen, Sipeng, Wei, Yongyue, Zhu, Ying, Li, Yi, Chen, Jiajin, Guan, Jingxing, Kiemeney, L.A.L.M., Chen, Feng, Christiani, David C., Zhang, Ruyang, Shen, Sipeng, Wei, Yongyue, Zhu, Ying, Li, Yi, Chen, Jiajin, Guan, Jingxing, Kiemeney, L.A.L.M., Chen, Feng, and Christiani, David C.
- Abstract
Contains fulltext : 283262.pdf (Publisher’s version ) (Open Access)
- Published
- 2022
45. Association of visceral and subcutaneous adiposity with tumor stage and Fuhrman grade in renal cell carcinoma
- Author
-
Maurits, J.S.F., Sedelaar, J.P.M., Aben, K.K.H., Kiemeney, L.A.L.M., Vrieling, A., Maurits, J.S.F., Sedelaar, J.P.M., Aben, K.K.H., Kiemeney, L.A.L.M., and Vrieling, A.
- Abstract
Contains fulltext : 284089.pdf (Publisher’s version ) (Open Access)
- Published
- 2022
46. A saturated map of common genetic variants associated with human height
- Author
-
Yengo, L., Vedantam, S., Marouli, E., Sidorenko, J., Bartell, E., Sakaue, S., Graff, M, Eliasen, A.U., Jiang, Y., Raghavan, S., Miao, J., Arias, J.D., Graham, S.E., Mukamel, R.E., Spracklen, C.N., Yin, X., Chen, Shiou-Shiou, Ferreira, T., Highland, H.H., Ji, Y., Karaderi, T., Lin, K., Lüll, K., Malden, D.E., Medina-Gomez, C., Machado, M., Moore, A., Rüeger, S., Sim, X., Vrieze, S., Ahluwalia, T.S., Akiyama, M., Allison, M.A., Alvarez, M., Andersen, M.K., Ani, A., Appadurai, V., Arbeeva, L., Bhaskar, S., Bielak, L.F., Bollepalli, S., Bonnycastle, L.L., Bork-Jensen, J., Bradfield, J.P., Bradford, Y., Braund, P.S., Brody, J.A., Burgdorf, K.S., Cade, B.E., Cai, H., Cai, Q., Campbell, A., Cañadas-Garre, M., Catamo, E., Chai, J.F., Chai, X., Chang, L.C., Chang, Y.C., Chen, Chen, Chesi, A., Choi, S.H., Chung, R.H., Cocca, M., Concas, M.P., Couture, C., Cuellar-Partida, G., Danning, R., Daw, E.W., Degenhard, F., Delgado, G.E., Delitala, A., Demirkan, A., Deng, X., Devineni, P., Dietl, A., Dimitriou, M., Dimitrov, L., Dorajoo, R., Ekici, A.B., Engmann, J.E., Fairhurst-Hunter, Z., Farmaki, A.E., Faul, J.D., Fernandez-Lopez, J.C., Forer, L., Francescatto, M., Freitag-Wolf, S., Fuchsberger, C., Galesloot, T.E., Gao, Y., Gao, Z., Geller, F., Giannakopoulou, O., Giulianini, F., Gjesing, A.P., Goel, A., Gordon, S.D.S., Gorski, M., Grove, J, Lores-Motta, Laura, Pauper, M., Hollander, A.I. den, Hoyng, C.B., Kiemeney, L.A.L.M., Visscher, P.M., Hirschhorn, J.N., Yengo, L., Vedantam, S., Marouli, E., Sidorenko, J., Bartell, E., Sakaue, S., Graff, M, Eliasen, A.U., Jiang, Y., Raghavan, S., Miao, J., Arias, J.D., Graham, S.E., Mukamel, R.E., Spracklen, C.N., Yin, X., Chen, Shiou-Shiou, Ferreira, T., Highland, H.H., Ji, Y., Karaderi, T., Lin, K., Lüll, K., Malden, D.E., Medina-Gomez, C., Machado, M., Moore, A., Rüeger, S., Sim, X., Vrieze, S., Ahluwalia, T.S., Akiyama, M., Allison, M.A., Alvarez, M., Andersen, M.K., Ani, A., Appadurai, V., Arbeeva, L., Bhaskar, S., Bielak, L.F., Bollepalli, S., Bonnycastle, L.L., Bork-Jensen, J., Bradfield, J.P., Bradford, Y., Braund, P.S., Brody, J.A., Burgdorf, K.S., Cade, B.E., Cai, H., Cai, Q., Campbell, A., Cañadas-Garre, M., Catamo, E., Chai, J.F., Chai, X., Chang, L.C., Chang, Y.C., Chen, Chen, Chesi, A., Choi, S.H., Chung, R.H., Cocca, M., Concas, M.P., Couture, C., Cuellar-Partida, G., Danning, R., Daw, E.W., Degenhard, F., Delgado, G.E., Delitala, A., Demirkan, A., Deng, X., Devineni, P., Dietl, A., Dimitriou, M., Dimitrov, L., Dorajoo, R., Ekici, A.B., Engmann, J.E., Fairhurst-Hunter, Z., Farmaki, A.E., Faul, J.D., Fernandez-Lopez, J.C., Forer, L., Francescatto, M., Freitag-Wolf, S., Fuchsberger, C., Galesloot, T.E., Gao, Y., Gao, Z., Geller, F., Giannakopoulou, O., Giulianini, F., Gjesing, A.P., Goel, A., Gordon, S.D.S., Gorski, M., Grove, J, Lores-Motta, Laura, Pauper, M., Hollander, A.I. den, Hoyng, C.B., Kiemeney, L.A.L.M., Visscher, P.M., and Hirschhorn, J.N.
- Abstract
Item does not contain fulltext, Common single-nucleotide polymorphisms (SNPs) are predicted to collectively explain 40-50% of phenotypic variation in human height, but identifying the specific variants and associated regions requires huge sample sizes(1). Here, using data from a genome-wide association study of 5.4 million individuals of diverse ancestries, we show that 12,111 independent SNPs that are significantly associated with height account for nearly all of the common SNP-based heritability. These SNPs are clustered within 7,209 non-overlapping genomic segments with a mean size of around 90 kb, covering about 21% of the genome. The density of independent associations varies across the genome and the regions of increased density are enriched for biologically relevant genes. In out-of-sample estimation and prediction, the 12,111 SNPs (or all SNPs in the HapMap 3 panel(2)) account for 40% (45%) of phenotypic variance in populations of European ancestry but only around 10-20% (14-24%) in populations of other ancestries. Effect sizes, associated regions and gene prioritization are similar across ancestries, indicating that reduced prediction accuracy is likely to be explained by linkage disequilibrium and differences in allele frequency within associated regions. Finally, we show that the relevant biological pathways are detectable with smaller sample sizes than are needed to implicate causal genes and variants. Overall, this study provides a comprehensive map of specific genomic regions that contain the vast majority of common height-associated variants. Although this map is saturated for populations of European ancestry, further research is needed to achieve equivalent saturation in other ancestries.
- Published
- 2022
47. Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer
- Author
-
Byun, Jinyoung, Han, Y., Li, Yafang, Xia, Jun, Long, Erping, Choi, Jiyeon, Xiao, Xiangjun, Zhu, Meng, Kiemeney, L.A.L.M., Hung, R.J., Amos, C.I., Byun, Jinyoung, Han, Y., Li, Yafang, Xia, Jun, Long, Erping, Choi, Jiyeon, Xiao, Xiangjun, Zhu, Meng, Kiemeney, L.A.L.M., Hung, R.J., and Amos, C.I.
- Abstract
Item does not contain fulltext
- Published
- 2022
48. Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci
- Author
-
DeVries, A.A.F., Dennis, J., Tyrer, J.P., Peng, P.C., Coetzee, S.G., Reyes, A.L., Plummer, J.T., Davis, B.D., Chen, S.S., Dezem, F.S., Aben, K.K.H., Anton-Culver, H., Antonenkova, N.N., Beckmann, M.W., Beeghly-Fadiel, A., Berchuck, A., Bogdanova, N.V., Bogdanova-Markov, N., Brenton, J.D., Butzow, R., Campbell, I., Chang-Claude, J., Chenevix-Trench, G., Cook, L.S., Defazio, A., Doherty, J.A., Dörk, T., Eccles, D.M., Eliassen, A.H., Fasching, P.A., Fortner, R.T., Giles, G.G., Goode, E.L., Goodman, M.T., Gronwald, J., Håkansson, N., Hildebrandt, M.A., Huff, C., Huntsman, D.G., Jensen, A., Kar, S., Karlan, B.Y., Khusnutdinova, E.K., Kiemeney, L.A.L.M., Kjaer, S.K., Kupryjanczyk, J., Labrie, M., Lambrechts, D., Le, N.D., Lubiński, J., May, T., Menon, U., Milne, R.L., Modugno, F., Monteiro, Ana, Moysich, K.B., Odunsi, K., Olsson, H., Pearce, C.L., Pejovic, T., Ramus, S.J., Riboli, E., Riggan, M.J., Romieu, I., Sandler, D.P., Schildkraut, J.M., Setiawan, V.W., Sieh, W., Song, H., Sutphen, R., Terry, K.L., Thompson, P.J., Titus, L., Tworoger, S.S., Nieuwenhuysen, E. Van, Edwards, D.V., Webb, P.M., Wentzensen, N., Whittemore, A.S., Wolk, A., Wu, A.H., Ziogas, Argyrios, Freedman, M.L., Lawrenson, K., Pharoah, P.D., Easton, D.F., Gayther, S.A., Jones, M.R., DeVries, A.A.F., Dennis, J., Tyrer, J.P., Peng, P.C., Coetzee, S.G., Reyes, A.L., Plummer, J.T., Davis, B.D., Chen, S.S., Dezem, F.S., Aben, K.K.H., Anton-Culver, H., Antonenkova, N.N., Beckmann, M.W., Beeghly-Fadiel, A., Berchuck, A., Bogdanova, N.V., Bogdanova-Markov, N., Brenton, J.D., Butzow, R., Campbell, I., Chang-Claude, J., Chenevix-Trench, G., Cook, L.S., Defazio, A., Doherty, J.A., Dörk, T., Eccles, D.M., Eliassen, A.H., Fasching, P.A., Fortner, R.T., Giles, G.G., Goode, E.L., Goodman, M.T., Gronwald, J., Håkansson, N., Hildebrandt, M.A., Huff, C., Huntsman, D.G., Jensen, A., Kar, S., Karlan, B.Y., Khusnutdinova, E.K., Kiemeney, L.A.L.M., Kjaer, S.K., Kupryjanczyk, J., Labrie, M., Lambrechts, D., Le, N.D., Lubiński, J., May, T., Menon, U., Milne, R.L., Modugno, F., Monteiro, Ana, Moysich, K.B., Odunsi, K., Olsson, H., Pearce, C.L., Pejovic, T., Ramus, S.J., Riboli, E., Riggan, M.J., Romieu, I., Sandler, D.P., Schildkraut, J.M., Setiawan, V.W., Sieh, W., Song, H., Sutphen, R., Terry, K.L., Thompson, P.J., Titus, L., Tworoger, S.S., Nieuwenhuysen, E. Van, Edwards, D.V., Webb, P.M., Wentzensen, N., Whittemore, A.S., Wolk, A., Wu, A.H., Ziogas, Argyrios, Freedman, M.L., Lawrenson, K., Pharoah, P.D., Easton, D.F., Gayther, S.A., and Jones, M.R.
- Abstract
Item does not contain fulltext, BACKGROUND: Known risk alleles for epithelial ovarian cancer (EOC) account for approximately 40% of the heritability for EOC. Copy number variants (CNVs) have not been investigated as EOC risk alleles in a large population cohort. METHODS: Single nucleotide polymorphism array data from 13 071 EOC cases and 17 306 controls of White European ancestry were used to identify CNVs associated with EOC risk using a rare admixture maximum likelihood test for gene burden and a by-probe ratio test. We performed enrichment analysis of CNVs at known EOC risk loci and functional biofeatures in ovarian cancer-related cell types. RESULTS: We identified statistically significant risk associations with CNVs at known EOC risk genes; BRCA1 (PEOC = 1.60E-21; OREOC = 8.24), RAD51C (Phigh-grade serous ovarian cancer [HGSOC] = 5.5E-4; odds ratio [OR]HGSOC = 5.74 del), and BRCA2 (PHGSOC = 7.0E-4; ORHGSOC = 3.31 deletion). Four suggestive associations (P < .001) were identified for rare CNVs. Risk-associated CNVs were enriched (P < .05) at known EOC risk loci identified by genome-wide association study. Noncoding CNVs were enriched in active promoters and insulators in EOC-related cell types. CONCLUSIONS: CNVs in BRCA1 have been previously reported in smaller studies, but their observed frequency in this large population-based cohort, along with the CNVs observed at BRCA2 and RAD51C gene loci in EOC cases, suggests that these CNVs are potentially pathogenic and may contribute to the spectrum of disease-causing mutations in these genes. CNVs are likely to occur in a wider set of susceptibility regions, with potential implications for clinical genetic testing and disease prevention.
- Published
- 2022
49. Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib
- Author
-
Diekstra, M.H.M., Swen, J.J., Zanden, L.F.M. van der, Vermeulen, S.H., Boven, E., Mathijssen, R.H., Fukunaga, K., Mushiroda, T., Hongo, F., Oosterwijk, E., Cambon-Thomsen, A., Castellano, D., Fritsch, A., Donas, J.G., Rodriguez-Antona, C., Ruijtenbeek, R., Radu, M.T., Eisen, T., Junker, K., Roessler, M., Jaehde, U., Miki, T., Böhringer, S., Kubo, M., Kiemeney, L.A.L.M., Guchelaar, H.J., Diekstra, M.H.M., Swen, J.J., Zanden, L.F.M. van der, Vermeulen, S.H., Boven, E., Mathijssen, R.H., Fukunaga, K., Mushiroda, T., Hongo, F., Oosterwijk, E., Cambon-Thomsen, A., Castellano, D., Fritsch, A., Donas, J.G., Rodriguez-Antona, C., Ruijtenbeek, R., Radu, M.T., Eisen, T., Junker, K., Roessler, M., Jaehde, U., Miki, T., Böhringer, S., Kubo, M., Kiemeney, L.A.L.M., and Guchelaar, H.J.
- Abstract
Contains fulltext : 251723.pdf (Publisher’s version ) (Open Access), Individual response to sunitinib in metastatic renal cell carcinoma (mRCC) patients is highly variable. Earlier, sunitinib outcome was related to single nucleotide polymorphisms (SNPs) in CYP3A5 and ABCB1. Our aim is to provide novel insights into biological mechanisms underlying sunitinib action. We included mRCC patients from the European EuroTARGET consortium (n = 550) and the RIKEN cohort in Japan (n = 204) which were analysed separately and in a meta-analysis of genome-wide association studies (GWAS). SNPs were tested for association with progression-free survival (PFS) and overall survival (OS) using Cox regression. Summary statistics were combined using a fixed effect meta-analysis. SNP rs28520013 in PDLIM3 and the correlated SNPs rs2205096 and rs111356738 both in DSCAM, showed genome-wide significance (p < 5 × 10(-8)) with PFS and OS in the meta-analysis. The variant T-allele of rs28520013 associated with an inferior PFS of 5.1 months compared to 12.5 months in non-carriers (p = 4.02 × 10(-10), HR = 7.26). T-allele carriers of rs28520013 showed an inferior OS of 6.9 months versus 30.2 months in non-carriers (p = 1.62 × 10(-8), HR = 5.96). In this GWAS we identified novel genetic variants in PDLIM3 and DSCAM that impact PFS and OS in mRCC patients receiving sunitinib. The underlying link between the identified genes and the molecular mechanisms of sunitinib action needs to be elucidated.
- Published
- 2022
50. Association Study between Polymorphisms in DNA Methylation-Related Genes and Testicular Germ Cell Tumor Risk
- Author
-
Grasso, C., Popovic, M., Isaevska, E., Lazzarato, F., Fiano, V., Zugna, D., Pluta, J., Weathers, B., D'Andrea, K., Almstrup, K., Anson-Cartwright, L., Bishop, D.T., Chanock, S.J., Chen, C, Cortessis, V.K., Dalgaard, M.D., Daneshmand, S., Ferlin, A., Foresta, C., Frone, M.N., Gamulin, M., Gietema, J.A., Greene, M.H., Grotmol, T., Hamilton, R.J., Haugen, T.B., Hauser, R., Karlsson, R., Kiemeney, L.A.L.M., Lessel, D., Lista, P., Lothe, R.A., Loveday, C., Meijer, C., Nead, K.T., Nsengimana, J., Skotheim, R.I., Turnbull, C., Vaughn, D.J., Wiklund, F., Zheng, T., Zitella, A., Schwartz, S.M., McGlynn, K.A., Kanetsky, P.A., Nathanson, K.L., Richiardi, L., Grasso, C., Popovic, M., Isaevska, E., Lazzarato, F., Fiano, V., Zugna, D., Pluta, J., Weathers, B., D'Andrea, K., Almstrup, K., Anson-Cartwright, L., Bishop, D.T., Chanock, S.J., Chen, C, Cortessis, V.K., Dalgaard, M.D., Daneshmand, S., Ferlin, A., Foresta, C., Frone, M.N., Gamulin, M., Gietema, J.A., Greene, M.H., Grotmol, T., Hamilton, R.J., Haugen, T.B., Hauser, R., Karlsson, R., Kiemeney, L.A.L.M., Lessel, D., Lista, P., Lothe, R.A., Loveday, C., Meijer, C., Nead, K.T., Nsengimana, J., Skotheim, R.I., Turnbull, C., Vaughn, D.J., Wiklund, F., Zheng, T., Zitella, A., Schwartz, S.M., McGlynn, K.A., Kanetsky, P.A., Nathanson, K.L., and Richiardi, L.
- Abstract
Item does not contain fulltext, BACKGROUND: Testicular germ cell tumors (TGCT), histologically classified as seminomas and nonseminomas, are believed to arise from primordial gonocytes, with the maturation process blocked when they are subjected to DNA methylation reprogramming. SNPs in DNA methylation machinery and folate-dependent one-carbon metabolism genes have been postulated to influence the proper establishment of DNA methylation. METHODS: In this pathway-focused investigation, we evaluated the association between 273 selected tag SNPs from 28 DNA methylation-related genes and TGCT risk. We carried out association analysis at individual SNP and gene-based level using summary statistics from the Genome Wide Association Study meta-analysis recently conducted by the international Testicular Cancer Consortium on 10,156 TGCT cases and 179,683 controls. RESULTS: In individual SNP analyses, seven SNPs, four mapping within MTHFR, were associated with TGCT risk after correction for multiple testing (q ≤ 0.05). Queries of public databases showed that three of these SNPs were associated with MTHFR changes in enzymatic activity (rs1801133) or expression level in testis tissue (rs12121543, rs1476413). Gene-based analyses revealed MTHFR (q = 8.4 × 10-4), methyl-CpG-binding protein 2 (MECP2; q = 2 × 10-3), and ZBTB4 (q = 0.03) as the top TGCT-associated genes. Stratifying by tumor histology, four MTHFR SNPs were associated with seminoma. In gene-based analysis MTHFR was associated with risk of seminoma (q = 2.8 × 10-4), but not with nonseminomatous tumors (q = 0.22). CONCLUSIONS: Genetic variants within MTHFR, potentially having an impact on the DNA methylation pattern, are associated with TGCT risk. IMPACT: This finding suggests that TGCT pathogenesis could be associated with the folate cycle status, and this relation could be partly due to hereditary factors.
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.